Parkland

Board of Managers

Agenda for the ***Board of Managers*** meeting of the Dallas County Hospital District is scheduled for ***Wednesday, December 17, 2025, at 12:50 PM (or immediately following HOMES meeting)*** at 5200 Harry Hines Blvd (WISH Building), Dallas, TX 75235, Conference Room 02-175. (If assistance is needed in locating the room, please see the Administration receptionist on the 4th floor, 04-131.) Videoconferencing access is also possible via Webex. That application is available at https://www.webex.com/downloads.html. Teleconferencing access is possible by calling +1-415-655-0001. Both virtual access forms require inputting (meeting number: 2300 250 4492; meeting password: 1234) to join the meeting. The ***Board of Managers*** reserves the right to exercise discretion and may convene in Executive Session as permitted by Texas Government Code §§551.071 (consultation with attorney), 551.072 (deliberations regarding real estate), 551.074 (personnel matters), 551.076 (deliberations regarding security devices or security audits), 551.078 and/or 551.0785 (deliberations by medical committee or by governmental body that administers a public insurance, health or retirement plan regarding individuals' medical or psychiatric records), 551.085 (deliberation by governing board of certain providers of health care services), 551.087 (deliberation regarding economic development negotiations), 551.088 (deliberation regarding test item); Texas Government Code §418.183 (deliberation of information under §§418.175 – 418.182 for purposes of disaster management or disaster planning); Texas Health & Safety Code §161.032 (medical committee or medical peer review committee records, information or reports; and/or medical committee or medical peer review committee proceedings under Tex. Health & Safety Code Chapter 161 and/or Tex. Occ. Code Chapters 151 and 160); and/or as otherwise authorized by law on any item listed below. The ***Board of Managers*** may consider any of the agenda items in open or executive session and may continue the meeting as necessary to accomplish the business at the time and place designated by the Chair to reconvene.

	PAGE	TIME (MIN)	PRESENTER(S)
I. Opening/Call to Order/Determine the Presence of a Quorum Present/Mission Statement/Opening Remarks ***Advance Wellness | Relieve Suffering | Develop and Educate*** **I CARE** **I**ntegrity **C**ompassion and Collaboration **A**ccountability **R**espect **E**quity The agenda has been developed by the Chief Governance Officer in consultation with the Board Chair and reviewed and affirmed by Counsel.			Chair
A. Invocation by Chaplin Michael Brumley		5	
B. Public Comments Regarding Non-Agenda Items See public comment registration information and rules at *https://www.parklandhospital.com/board-of-managers*			
C. Public Comments Regarding Agenda Items See public comment registration information and rules at *https://www.parklandhospital.com/board-of-managers*			
II. Consent Agenda: Minutes			Chair
A. Consideration and Appropriate Action Regarding Minutes 2025-11-05 Governance, Compliance and Ethics Committee	*7*		
B. Consideration and Appropriate Action Regarding Minutes 2025-11-05 Talent Development and Executive Compensation Committee	*11*		
C. Consideration and Appropriate Action Regarding Minutes 2025-11-18 Budget & Finance Committee	*15*		
D. Consideration and Appropriate Action Regarding Minutes 2025-11-19 Quality of Care & Patient Safety Committee	*22*		
E. Consideration and Appropriate Action Regarding Minutes 2025-11-19 Board of Managers	*27*		

		PAGE	TIME (MIN)	PRESENTER(S)
III.	**Consent Agenda: Contracts**			Chair
A.	Consideration and Appropriate Action Regarding Contracts over $200,000 **(See Attached List of Contracts)**	*36*		
IV.	**Consent Agenda: Capital Substitution(s)**			
A.	Consideration and Appropriate Action Regarding Capital Substitution(s) **(See Attached List of Capital Substitution(s))**	*66*		
V.	**Consent Agenda: Policies**			
A.	Consideration and Appropriate Action Regarding Fiscal 8311-1-04 Investment Policy	*69*		
VI.	**Consent Agenda: Other**			Chair
A.	Consideration and Appropriate Action Regarding Authorizing Officer for the 340B Program	*102*		
B.	Consideration and Appropriate Action Regarding - Investment Committee Report and Recommendation – Private Markets Investment Manager	*104*		
VII.	**Consent Agenda: Medical Executive Committee Items**			Chair
A.	Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers	*126*		
VIII.	**Reports Requiring Deliberation(s) and/or Approval**			
A.	Governance Update and Discussion Regarding Key Upcoming Dates and the Board Self Assessment	*128*	5	Chair
B.	CEO Update on System Operations	*129*	10	Fred Cerise, MD
C.	Parkland Pension Plan Funding Status	*130*	30	Milliman
D.	Parkland Debt Capacity and Alternatives	*147*	30	Hilltop
IX.	**Break**			
X.	**Executive Session**			
A.	Discussion Regarding Potential New Service Lines and Property Acquisition *Tex. Gov't Code §551.072 & §551.085*	*203*	120	Blue Cottage of Cannon Design
XI.	**Executive Session – Possible Deliberation**			
A.	Possible Deliberation Regarding Medical Executive Committee Credentialing Report Tex. Health & Safety Code §161.032	*204*		

		PAGE	TIME (MIN)	PRESENTER(S)
B.	Possible Deliberation Regarding Medical Executive Committee Delineation of Privileges Tex. Health & Safety Code §161.032			
i.	Oral and Maxillofacial Surgery (OMFS)	*221*		
ii.	Internal Medicine	*230*		
iii.	Endocrinology	*234*		
iv.	Gastroenterology	*240*		
v.	Infectious Disease	*248*		
XII.	**Reports Requiring Deliberation(s) and/or Possible Action**			Chair
A.	Possible Deliberation Regarding Q3 Sole Source Report	*253*		
B.	Possible Deliberation Regarding Q4 Sole Source Report	*256*		
C.	Possible Deliberation Regarding Board of Managers Attendance Report	*259*		
D.	Possible Deliberation Regarding Board of Managers Meeting Evaluation Report	*261*		
XIII.	**Action Items**			Chair
A.	Board May Take Action on Any Agenda Item(s) Above			
XIV.	**Adjourn**			Chair
A.	Closing Remarks			
B.	Call to Adjourn			

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.
									December 17, 2025
				Medical Products and Services					
M1	Capital	Walk-Away Specimen Processor (WASP) and Accessories	Beckman & Coulter, Inc.	Last Signature – 12/4/2026	$365,302	$365,302	GPO Purchase	Yes	Bernie Buenvenida/Clinical Engineering
M2	Expense	Mod # 10 Medtronic Neuro Interventional Products	Medtronic USA, Inc.	10/24/2018 - 12/31/2027	$406,000	$2,641,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shawn Grady/Interventional Radiology
M3	Expense	Mod # 8 Microvention Neuro Interventional Products	Microvention, Inc.	7/1/2019 -12/31/2027	$730,000	$3,567,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shawn Grady/Interventional Radiology
M4	Expense	Mod # Streck Laboratories BCT Tubes	Streck Laboratories	1/1/2024 -12/31/2026	$400,000	$800,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristian Faulk/Scott Hampton/Laboratory Services - Chemistry
M5	Capital and Expense	Purchase of the Solventum V.A.C Ulta Negative Pressure Wound Therapy units.	Solventum	12/17/2025 – 5/19/2026	$729,612	$729,612	GPO Purchase	Yes	Pamela Bryant/Supply Chain

Construction and Facilities									
C1	Capital	Mod # 1 Additional Service #5	Corgan Associates, Inc.	8/31/2023 -6/11/2027	$42,475	$1,115,405	Non-Sole Source Modification	Yes	Paul Woodard/Planning Design and Construction
C2	Expense: Court Approval	Mod # 1 First Amendment to Office Lease Agreement	Homeward Bound, Inc.	6/1/2022-5/31/2030	$0	$0	Sole Source Modification	N/A-Zero Dollar	Beall Carothers/Planning Design & Construction
Hospital Operations									
O1	Expense	Telephone Answering Services	New Orleans Teleport dba Calls Plus	4/2/2026 – 4/1/2031	$447,000	$447,000	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Prentiss Wright/Call Center Operations
O2	Revenue	Mod #8 MIPS/TIPPS Reporting Services (Revenue)	The University of Texas Southwestern Medical Center	3/9/2022-9/30/2026	($374,841)	($2,121,231)	Contract Extension without Competition	N/A-Revenue	Keri Disney-Story/Finance Administration
O3	Expense	Mobile Medical Clinic	Farber Specialty Vehicle	12/18/2025 – 12/17/2026	$732,737	$732,737	Sole Source	Yes	Kyla Rankin/Homes
O4	Expense	Childcare Operations Provider	Learning Care Group	1/1/2026 – 12/31/2030	$1,061,827	$1,061,827	Request for Proposals (Best Value)	Yes	Ryan Alcantar & Miranda Bond/Office of Talent Management

Parkland Health
FY2026 Capital Substitution
For December 2025 Board Meeting

Ref #	Division	Project Total	Substitution Amount	Description
1	Facilities and Perioperative Services	$3,648,128	$1,698,526	Facility Expansion and Equipment for Procedure Rooms at the Simmons Ambulatory Surgical Center (ASC)
	Explanation	The purpose of this capital request is to increase surgical procedures at the Simmons Ambulatory Surgical Center (ASC), which is located at the intersection of Medical District Drive and Harry Hines Blvd. Currently, there are two procedure rooms at the ASC that are being used for equipment storage. To optimize the patient care space and improve operations, a capital request to build 1,213 square feet of storage space was approved, which would allow the two procedure rooms to be utilized for patient care. A change in scope requires an increase to the capital budget. In the revised scope, the square feet for storage increased to 2,266 square feet based on the additional services that will be provided at the ASC and long term storage needs. The ASC is projected to continue operations at its current location for the next 20 years. Approval of this request will allow the opportunity to increase ophthalmic laser, pain, and coloscopy procedures. As services expand at the ASC, additional equipment will be required to support the expanded services and space will be needed to accommodate the additional medical equipment (i.e., colonoscopy equipment and surgical robots). As of 12/8/25, there are $21,377,965 available in contingency funds.		
	Driver(s) of Increased Expense:	Additional space to meet long term storage needs; colonoscopy equipment		
	Description of Item:	Storage space; colonoscopy equipment		
	Grand Total	**$3,648,128**	**$1,698,526**	

Invocation

Consideration and Appropriate Action Regarding Minutes 2025-11-05 Governance, Compliance and Ethics Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

GCEC
November 5th, 2025

Minutes of the Governance, Compliance and Ethics Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, November 5th, 2025, scheduled for 11:00 a.m. in the WISH Building Executive Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Reina Gonzalez, JD, noted that a quorum was physically present and called the meeting to order at 11:00 a.m. Committee members; Byron Cryer, MD, Yasmin Simon, JD, Lisa Sutter and Ramon Miguez, PE attended in-person.

Board Member Attendees Included: Vincent Hall and Marjorie Petty, JD.

Staff Present (via Webex and in-person) included:

Brad Nitschke, Interim Chief Legal Officer
Edmundo Castaneda, EVP & COO
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & CEO
Melanie Roberts, SVP/Chief Compliance & Ethics Officer
Michelle Ng, Administrative Resident
Morgan Simmons, Governance Program Coordinator
Roshan Thayil, Sr. Director Compliance Programs
Saul Cordero, SVP & Chief Governance & Strategy Officer

II. Mission Statement

Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports requiring Deliberation(s) or Possible Action

Melanie Roberts announced to the Board that November 2-8, 2025, is Corporate Compliance & Ethics Week.

A. Presentation of Charters of the Standing Committees of the Board of Managers

Saul Cordero presented all the Board Committee charters and the relevant changes to the GCEC Committee. Saul noted that there were no substantial changes made to the charters except for the clarification statements to the attendance structure for both Audit and TDEC committees.

Reina Gonzalez asked for a motion to recommend the charters for final approval at the full Board meeting. Ramon Miguez motioned. Byron Cryer seconded the motion. The motion carried unanimously.

B. Presentation of Proposed Changes to Parkland Policy SYS.COMP.039, Reporting Obligations

Melanie Roberts presented the updated Reporting Obligations Policy to the GCEC Committee, explaining that the policy educates workforce members on compliance and ethics-related reporting requirements and emphasizes their duty to report potential issues to Compliance for independent assessment of any substantiated risks. She noted that the policy has been in place for several years, with the last version published in 2022, and highlighted a key revision: the removal of the health plan from the policy scope, as it maintains its own reporting structure and mechanism. Questions arose regarding the independence of the PCHP compliance officer compared to Parkland Health's structure, leading to a suggestion that the PCHP Board review its compliance reporting structure.

Reina Gonzalez requested a motion for approval of the policy to the full Board. The committee then moved to recommend approval of the updated policy with one caveat—that the PCHP Board evaluate its current compliance reporting structure and determine if changes are needed. Ramon Miguez motioned for approval. Lisa Sutter seconded the motion. The motion caried unanimously.

VI. Executive Session

At 11:12 a.m., the Committee went into executive session to discuss the items on the Executive Session agenda.

Members of management were excused from the discussion of topics as necessary.

A. Review and Potential Discussion on the Following Compliance and Ethics Reports
(Tex. Health & Safety Code §§161.032 & 161.0315 and Tex. Occup. Code §160.007)
   i. FY25 Chief Compliance and Ethics Officer Annual Program Assessment
   ii. FY26 Compliance Work Plan Focus Areas

B. Attorney-Client Privileged & Confidential
Review and Discussion of Quarterly Report of Open Compliance Reviews and Audit Reports
(Tex. Gov't Code §551.071)

Committee Chair Reina Gonzalez, JD, adjourned the Executive Session and moved into Open Session at 12:12 p.m.

VII. Adjourn

With no further business to discuss, Committee Chair Reina Gonzalez, JD, adjourned the meeting at 12:12 p.m.

SO RECORDED:

Reina Gonzalez, JD Committee Chair	Todd Furniss, JD Secretary

Consideration and Appropriate Action Regarding Minutes 2025-11-05 Talent Development and Executive Compensation Committee

Minutes of the Talent Development and Executive Compensation Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, November 5th , 2025, scheduled for 12:30 p.m. or directly following the Governance, Compliance & Ethics Committee in the WISH Building Executive Conference Room (02-175) at Parkland Health and via Webex. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Lisa Sutter noted a quorum was physically present and called the meeting to order at 12:20 p.m. Committee members Farida Minner, RN, Vincent Hall, Eric G. Bing, MD, and Elizabeth Palacios, MD, were present.

Board Member attendees included: Marjorie Petty, JD and Ramon Miguez, PE.

Staff Present (via Webex and in-person) included:

Brad Nitschke, Interim Chief Legal Officer
Dan Enright, Director/Talent Mgmt. Analytics
DeLancey Johnson, SVP & Associate Chief Talent Officer
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & Chief Executive Officer
Jessica Hernandez, SVP & Chief Health Equity Officer
Michelle Ng, Administrative Resident
Melanie Roberts, SVP Chief Compliance and Ethics Officer
Morgan Simmons, Governance Program Coordinator
Saul Cordero, SVP & Chief Governance & Strategy Officer
Shauntee Mayfield, VP Chief Experience Officer
Sean Gorman, Mgr., Communications
Stacy Dorsey, SVP Workforce Strategy
Stephanie Speights, SVP/Talent Mgmt Development
Rick Humphrey, EVP & CFO

II. Mission Statement

Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval(s)

A. Office of Talent Management Overview of Department Level Goals and Commitment
Felicia Miller reminded the Board of Parkland's commitment to be the employer of choice for those with a calling to serve through transformational experience. The Office of Talent Management upholds this commitment through recruitment, development, rewards and engagement.

B. Workday: Progress Report, Organizational Impact and Key Milestones Achieved

C. Dr. DeLancey Johnson and Stacy Dorsey provided an update on the Workday implementation, Parkland's new human capital management system launching in January. Workday will replace PeopleSoft, SAP, and SuccessFactors, consolidating approximately 1,500 business processes into one platform. A dual maintenance approach will run in December, with Workday becoming the primary system on January 1, while legacy systems remain accessible for a year. Guiding principles include simplicity, standardization, and accurate payroll during transition. Communication efforts feature readiness surveys, monthly updates, training, SharePoint resources, and huddle sheets to reach non-desk employees. December will focus on significant policy changes and process impacts.

D. Developments in Workforce Strategy: DISD Partnership and Dallas College Update
Stephanie Speights shared that since the last update, one major change occurred: on September 13, an impactful "Focus High School" event was held with 36 schools represented, targeting grades 8–12. The event introduced students to high-demand healthcare careers beyond clinical roles, including imaging and IT. Feedback was highly positive. Stephanie also highlighted progress on formalizing a partnership agreement with Dallas College to strengthen collaboration and career pathways. Appreciation was expressed for leadership and team efforts.

E. Next Steps to Address One Parkland Survey Results
Dr. Shauntee Mayfield provided a brief update on employee engagement. Dr. Mayfield presented the action planning approach to address the next steps regarding the survey results. Action planning involves categorizing engagement scores for each leader and team, then assigning improvement activities based on those scores. In October, refresher sessions and a survey guide were provided, with recordings available for later access. Press Ganey conducted two in-person sessions during the week of October 29, and a 4-hour training for new leaders focused on understanding and improving engagement.

Support resources are tailored by leader index scores. The initiative also emphasizes connecting engagement efforts with patient experience through collaborative work.

F. Benefits Update: Progress and Recent Work
Dr. Johnson provided an overview of benefit strategy focused on cost control. Key priorities include reducing foreign medical spending, increasing domestic and affiliate utilization, and leveraging Parkland services for savings and 340B benefits. Efforts include direct provider contracts, improved access to primary and specialty care, and planning design changes for high-cost items like infusions and GLP-1 medications. A new wellness committee was launched to enhance benefit navigation and education. Additionally, agile budgeting now accounts for seasonal utilization trends. Dr. Johnson highlighted a successful PTO donation campaign, raising significant hours to support employees facing disability or leaving challenges.

VI. Executive Session

At 1:00 p.m., the Committee went into executive session to discuss the items on the Executive Session agenda.

Members of management were excused from the discussion of topics as necessary. Only Dr. Fred Cerise and Felicia Miller remained present in the room.

A. CEO Performance Appraisal Discussion ***Tex. Government Code §§551.074***

Lisa Sutter, adjourned Executive Session and moved into Open Session at 1:33 p.m.

VII. Adjourn

With no further business to discuss, Marjorie Petty adjourned the meeting at 1:33 p.m.

SO RECORDED:

Lisa Sutter Committee Chair	Todd Furniss, JD Secretary

Consideration and Appropriate Action Regarding Minutes 2025-11-18 Budget & Finance Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Budget and Finance
November 18th, 2025

Minutes of the Budget & Finance Committee meeting of the Dallas County Hospital District, held Tuesday, November 18th, 2025, scheduled for 11:30 AM in the WISH 02-175 Executive Conference Room at Parkland Health and via Webex. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Ramon Miguez, PE, noted that a quorum was physically present and called the meeting to order at 11:31 a.m. Committee members Vincent Hall, Byron Cryer, MD, and Yasmin Simon, JD, attended in person.

Board Member attendees included: Board Chair Marjorie Petty, JD.

Staff Present (via Webex and in-person) included:

Anthony Davis, Dir., Financial Operations
Brad Nitschke, Interim Chief Legal Officer
Brett Moran, Chief Health Officer
Edmundo Castaneda, EVP & COO
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & Chief Executive Officer
Guy Toliver, Dir Inclusion-Supply Diversity
Joe Longo, SVP & Chief Information Officer
Keri Disney-Story, VP/Clinical Finance
Michelle Ng, Administrative Resident
Morgan Simmons, Governance Program Coordinator
Pam Bryant, SVP Chief Supply Chain Officer
Saul Cordero, SVP & Chief Governance & Strategy Officer
Steven Roth, EVP & Chief Legal Officer

Other Attendees:
N/A

II. Mission Statement

The Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After reviewing the agenda, the Chair noted that the board members present had zero conflicts of interest.

A. Reports Requiring Deliberation(s) or Approval(s)

A. Consideration and Appropriate Action Regarding Contracts over $200,000

Pam Bryant reviewed the briefing documents for contracts over $200,000. (See Appendix A for these minutes for more specific details on each contract). Pam Bryant presented each contract based on expense, capital, revenue, and selection method (sole source and non-sole source).

The Committee asked questions and received additional information related to the consideration of contracts over $200,000.

Ramon Miguez asked for a motion to approve contracts over $200,000. Byron Cryer motioned for approval. Vincent Hall seconded. The motion carried unanimously.

B. Consideration and Appropriate Action Regarding Capital Substitution(s)

Keri Disney-Story presented the capital substitution for the month. This project request includes the renovation of the Bluitt Flowers COPC, clinic relocations, and the optimization of space at other COPC locations in the southern region. This request will provide additional space for patient care activities, allow the expansion of specialty care in the community, and provide access to onsite pediatric behavioral health services at the CV Roman COPC. Also, two clinics will be combined, which will improve managerial oversight and reduce lease expenses. This request seeks approval to utilize funds that were previously budgeted for other projects at Bluitt Flowers and CV Roman. The relocation and consolidation of services will improve patient experience by moving to locations that are located on the DART bus routes, easier access to clinic locations and additional services out in the community.
The original budget request for the Bluitt Flowers renovation project was to convert business office space to clinical space, which would have created three exam rooms, one provider office, and one storage closet. The revised request will create three exam rooms, one consultation room, and six staff workstations in a pod that will be used for specialty care.

Ramon Miguez asked for a motion to approve the capital substitution. Vincent Hall motioned for approval. Yasmin Simon seconded. The motion carried unanimously.

C. Consideration and Appropriate Action Regarding Fiscal 8311-1-04 Investment Policy Regarding Parkland HMO Operating Funds

The committee conducted its annual review of the investment policy governing Parkland Hospital's operating assets (approximately $1.1 billion). Most revisions were routine language updates and minor adjustments. Key changes include:

- Adding Hilltop Securities as an investment management firm and educational resource.
- Updating references to the North Central Texas Council of Governments for training.
- Allowing sales of securities prior to maturity to meet liquidity needs.
- Removing outdated terms and eliminating mortgage pool securities as an approved investment type.

The policy remains aligned with the Texas Public Funds Investment Act and prioritizes safe investments in government securities. No objections were raised, and a motion for board approval was proposed.

Ramon Miguez asked for a motion to approve the investment policy. Vincent Hall motioned for approval. Yasmin Simon seconded. The motion carried unanimously.

D. Update and Report Parkland Financial Performance Presentation

For the month of October, Parkland Health recognized a net income of $13.2M which is $5.1M higher than the budgeted net income of $8.1M and $9.9M favorable compared to the prior year net income of $3.3M. Parkland Health's operating margin and operating cash flow margin for the month of October are 1.02% and 3.71%, respectively. The operating margin was favorable compared to budget of 0.08% and the operating cash flow margin is favorable compared to budget of 2.94%. Parkland Health's operating margin is favorable compared to prior year operating margin of 1.0% and favorable to the operating cash flow margin of 4.2% from the prior year. Parkland Health's patient cash collections in October were $114.2M which is higher than budget by $0.2M and $5.9M higher than the prior year. Parkland Health's days cash on hand of 200.9 days for the month is a decrease of 21.1 days compared to prior month of 222.0 days and compared to the prior year October of 187.2 days, an increase of 13.7 days.

Keri Disney-Story presented the key financials for the month of October as well as year-to-date statistics. Keri mentioned that Parkland's net income reached $13.2M versus $8.1M budget, driven by the free drug program, which added $6M in revenue but increased supply costs. Salaries were slightly over budget due to higher volumes and acuity, while purchased medical services were under budget with improved collections under the MSA contract. Across all entities, operating income was near target, and total income exceeded budget by $3M, largely from interest income. Government programs

showed a $24M favorable variance from Atlas program payments, offset by $28M in claims; Atlas is a new Medicaid quality incentive program causing timing variances. Key statistics included strong discharges and visits, with surgeries slightly down and deliveries significantly down, reflecting market trends. Cash remains strong despite an expected November dip before tax revenues; patient collections were delayed by CHIRP approval, with payments anticipated in early 2026. Accounts receivable improved after reassessing bad debt.

A. Follow-Up Requests

B. Closing Remarks

C. **Adjourn**

With no further business to discuss, Committee Chair Ramon Miguez, PE, adjourned the meeting at 12:11 pm.

SO RECORDED:

_____	_____
Ramon Miguez, PE	Todd Furniss, JD
Committee Chair	Secretary

Appendix A (Contracts Reviewed for Appropiate Action)

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
												November 19, 2025
Medical Products and Services												
M1	Expense	Mod # 3 Intraocular Lenses and Hydrus Microstents	Alcon Vision, LLC	11/14/2021-12/31/2027	$2,010,000	$5,146,180	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Perioperative Services	N/A	N/A	N/A
M2	Expense	Venaseal & ClosureFast Products	Medtronic USA, Inc.	12/24/2025 – 12/23/2030	$985,000	$985,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shawn Grady/Interventional Radiology	N/A	N/A	N/A
M3	Expense	Mod # 1 Omni Surgical System	Sight Sciences, Inc	5/25/2022-5/24/2026	$150,000	$444,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Ambulatory Service Center	N/A	N/A	N/A
M4	Expense	Mod # 1 Hospice Care Services	Forefront Living Hospice, Pathway Hospice, LLC. & The Visiting Nurse Association of Texas	7/1/2024 -6/30/2029	$2,600,000	$3,550,000	Non-Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shannan Bradley/Care Management Post Acute Services	0%	N/A	N/A
M5	Expense	Mod # 6 add funding and extend agreement through November 30, 2028	Premier Radiology Services, LLC	8/1/2020 -11/30/2028	$2,211,023	$4,111,438	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Tina Hill/ Crystal Harrison/Correctional Health/ Radiology	N/A	N/A	N/A
Construction and Facilities												
C1	Expense: Court Approval	Contract to Purchase 5415 Gregg Steet, ±0.5051 acres of land, Dallas, Texas	Gregg Street, LLC	Upon contact execution – plus 150 days for inspection & closing	$2,000,000	$2,000,000	Real Estate – Exemption	Yes	Beall Carothers/Planning Design & Construction	N/A	N/A	N/A
Information Technology												
IT1	Expense	Mod # 1 Add Web Hosting and Direct Data Configuration Services	Wellsky Corporation	11/21/2017-11/18/2030	$828,960	$4,241,047	Sole Source Modification	Yes	Greggory Ervin / LeMar Oleson/Information Technology	N/A	N/A	N/A

Parkland Health
FY2026 Capital Substitution
For November 2025 Board Meeting

Ref #	Division	Project Total	Substitution Amount	Description
1	COPC/Ambulatory Specialty Clinics	$1,455,420	$1,036,920	Bluitt Flowers COPC Renovation/Optimization and Clinic Relocations
	Explanation	This project request includes the renovation of the Bluitt Flowers COPC, clinic relocations, and the optimization of space at other COPC locations in the southern region. This request will provide additional space for patient care activities, allow the expansion of specialty care in the community, and provide access to onsite pediatric behavioral health services at the CV Roman COPC. Also, two clinics will be combined, which will improve managerial oversight and reduce lease expenses. This request seeks approval to utilize funds that were previously budgeted for other projects at Bluitt Flowers and CV Roman. No renovations have been made to the CV Roman Clinic. The timing of those meeting with key stakeholders occurred after the budget submission. During discussions regarding the implementation of the original CV Roman project, leaders from operations, nursing, and the physician group all agreed that utilizing the funds for the Bluitt Flowers & CV Roman renovations would yield a better return on investment. This request has been briefed by the facilities committee. The relocation and consolidation of services will improve patient experience by moving to locations that are located on the DART bus routes, easier access to clinic locations and additional services out in the community. The original budget request for the Bluitt Flowers renovation project was to convert business office space to clinical space, which would have created three exam rooms, one provider office, and one storage closet. The revised request will create three exam rooms, one consultation room, and six staff workstations in a pod that will be used for specialty care. Also, a nurse station will be added to include five cubicles and one office. The renovation will also include the reconfiguration of the IT room to minimize any potential life safety issues. To optimize space, there will also be several clinic relocations. Specialty services will move from CV Roman to Bluitt Flowers and allow OPC to expand services in the community. Pediatrics will move from Oak West to CV Roman and will provide access to onsite pediatric behavioral services. The CV Roman and Wynnewood ARCs will both move to Oak West and will be combined. This will improve managerial oversight and reduce lease expenses.	
	Driver(s) of Increased Expense:	Additional renovation at Bluitt Flowers; clinic relocations to optimize space;		
	Description of Item:	Bluitt Flowers Clinic renovation; clinic relocations		
	Grand Total	**$1,455,420**	**$1,036,920**	

Consideration and Appropriate Action Regarding Minutes 2025-11-19 Quality of Care & Patient Safety Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Quality of Care and Patient Safety
November 19th, 2025

Minutes of the Quality of Care and Patient Safety Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, November 19th, 2025, scheduled for 10:00 a.m. in the WISH building Executive Conference Room 02-175 at Parkland Health and via Webex. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Elizabeth Palacios, MD, noted that a quorum was physically present and called the meeting to order at 10:00 a.m. Committee members Eric G. Bing, MD (via Webex), and Farida Minner, RN Byron Cryer, MD, and Todd Furniss, JD attended in person.

Board Member attendees included: Marjorie Petty, JD, Ramon Miguez, PE, and Vincent Hall.

Staff Present (via Webex and in-person) included:
Brad Nitschke, Interim EVP Legal Affairs
Brett Moran, Chief Health Officer
Carmen Bowling, SVP Nursing
David Alexander, SVP Nursing
Dawn Marchetto, SVP Nursing
Donna Richardson, EVP & Chief Nursing Officer
Edmundo Castañeda, EVP & Chief Operating Officer
Fred Cerise, President & CEO
Gretchen Blake, VP Quality & Clinical Effectiveness
James Griffin, President of the Medical Executive Committee
Judy Herrington, SVP Nursing via Webex
Karen Garvey, VP Safety & Clinical Risk Management
Kathleen Doherty, VP Nursing Surgical Services
Maggie Palmer, VP/Medical Staff Professional Services
Margaret Dutton, Mngr., Operations COPC
Michael Lane, SVP & Chief Quality and Safety Officer
Michelle Ng, Administrative Resident
Morgan Simmons, Governance Program Coordinator
Saul Cordero, SVP & Chief Governance & Strategy Officer
Sobha Fuller, SVP Nursing

Attendees via Webex:
Ryan Mauck, MD – Service Chief, Urology; Pres-Elect – Med Staff
DeLancey Johnson - Senior Vice President, Associate Chief Talent Officer
Sonya Manibusan, CCP - Senior Director, Volunteer and Guest Services
Marlin Suell, MBA – Chief, Dallas County Hospital District Police
Charity Onyegbule
Stephen Harder, MD FACP - Medical Director, Hospital at Home
Alissa Tran, PharmD, BCCCP - Director, Acute Care at Home

Parkland

MINUTES
Dallas County Hospital District Board of Managers

Quality of Care and Patient Safety
November 19th, 2025

II. Mission Statement

Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Executive Session – Quality & Patient Safety Operations Section

At 10:01 a.m. the Committee moved into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics, as necessary.

In executive session, the Committee received the presentation and reports as specified in the posted agenda.

I. Executive Session: Quality & Patient Safety Operations (QSO)
Tex. Health & Safety Code §§161.032 & 161.0315 and Tex. Occupations. Code §160.007

A. **Update and Report by Chief Quality and Safety Officer**
Includes briefing from Executive Quality Committee (EQC)

B. **Review of Safety Event Cause Analysis (CA) Case(s)**
Shared learnings from recent safety event(s) with associated guide

C. **Update and Report Regarding Quality-Related Key Performance Indicators (KPIs)**
Reports for quality improvement project(s) throughout the enterprise

1. Department Performance Improvement Committee (PIC)/ Clinical Quality Committee (CQC) Annual Presentation(s)
Annual report from service lines related to quality and safety
   a. Population Health: Garland Health Center New Patient Access and Wait Times

2. Update and Report Regarding Hospital at Home Program

II. Possible Deliberation Regarding the Following

A. Executive Summaries
Overview of QSO departmental reports

B. Cause Analysis (CA) Log
List of upcoming cause analysis case reviews

~ end of Quality Portion of QBOM Agenda

VI. Executive Session: Medical Executive Committee ("MEC")

James D. Griffin, MD, President of the Medical Executive Committee, discussed the items posted on the agenda starting at 11:31 am.

A. Consideration and Appropriate Action Regarding Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

1. Medical Staff and Non-Physician Clinical Providers to Parkland Health
   a. Credentialing Report
2. Consideration and Appropriate Action Regarding Medical Staff Bylaws
   a. Technical Amendment – Podiatry
   b. Alignment with Operations Update – CCO Updates
3. Consideration and Appropriate Action Regarding Board Resolution: Maternal Levels of Care Plan Program - 2026

VII. Executive Session: Discussion regarding report and/or information provided by the Chief Quality Safety Officer and related items on this agenda.

The Committee did not conduct a discussion with the Chief Quality & Safety Officer, SVP, Michael Lane, without other members of management present.

VIII. Executive Session: Discussion regarding report and/or information provided by the Medical Executive Committee President and related items on this agenda.

The Committee conducted a discussion with the Medical Executive Committee President, Dr. James Griffin without other members of management present.

Chair adjourned Executive Session and moved into Open Session at 11:56 am.

IX. Action Items (Open Session)

A. Consideration and Appropriate Action Regarding MEC Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers
   1. Credentialing Report

B. Consideration and Appropriate Action Regarding Medical Staff Bylaws
   1. Technical Amendment – Podiatry
   2. Alignment with Operations Update – CCO Updates

C. Consideration and Appropriate Action Regarding Board Resolution: Maternal Levels of Care Plan Program - 2026

Todd Furniss motioned to approve the Medical Executive Committee Recommendations, Credentialing Report, Bylaws and Maternal Levels of Care Program Resolution. Byron Cryer seconded the motion. The motion passed unanimously.

X. Follow-Up Requests: None

XI. Closing Remarks

XII. Adjourn

With no further business to discuss, Committee Chair Elizabeth Palacios, MD, adjourned the meeting at 11:57 am.

SO RECORDED:

Elizabeth Palacios, MD Committee Chair	Todd Furniss, JD Secretary

Consideration and Appropriate Action Regarding Minutes 2025-11-19 Board of Managers

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Board
November 19th, 2025

Minutes of the Board of Managers meeting of the Dallas County Hospital District, held Wednesday, November 19th, 2025, scheduled for 12:50 PM (or immediately following the HOMES meeting) in the WISH 02-175 Executive Conference Room at Parkland Health and via Webex. These minutes do not constitute a certified agenda for the meeting.

I. Attendance and Call to Order

Chair Marjorie Petty noted that a quorum was physically present and called the meeting to order at 1:15 PM.

Board Member attendees included: Vincent Hall, Lisa Sutter, Todd Furniss, JD, Eric G Bing, MD, PhD (via Webex), Farida Minner, RN, Byron Cryer, MD, Ramon Miguez, PE, Elizabeth Palacios, MD, and Yasmin Simon, JD.

Staff Present (via Webex and in-person) included:

Barry-Lewis Harris, Sr. Medical Dir. Correction Health
Brett Moran, Chief Health Officer
Brad Nitschke, Interim Chief Legal Officer
Carolyn Foster, VP Deputy General Counsel
Donna Richardson, EVP & Chief Nursing Officer
Edmundo Castañeda, EVP & Chief Operating Officer
Francesco Mainetti, SVP Ambulatory Clinic Operations
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & Chief Executive Officer
Jared Ginter, VP Institutional Risk Mgmt.
Jessica Hernandez, SVP & Chief Health Equity Officer
Joseph Chang, Chief Medical Officer
JD Buchert, Workforce Safety Manager
Keri Disney-Story, VP/Clinical Finance
Michelle Ng, Administrative Resident
Michael Lane, SVP & Chief Quality and Safety Officer
Morgan Simmons, Governance Program Coordinator
Pam Bryant, SVP/Supply Chain Management
Roshan Thayil, Sr., Director Compliance Programs
Saul Cordero, SVP & Chief Governance & Strategy Officer
Steven Roth, EVP & Chief Legal Officer
Teresita Oaks, Dir., Community Health Programs
Vivian Johnson, SVP Community Health (via Webex)

Additional Attendees:
Commissioner John Wiley Price
Edna Ruano, Government Relations Manager (via Webex)
Socorro Salazar, Dallas County Staffer (via Webex)
Melissa Clay, NTBHA

Kimberly Oxley, NTBHA
Chief Deputy Robinson, Correctional Health
Chief Deputy Sowell, Correctional Health

Senior Director Williams, Correctional Health
Quality Nurse Maxwell, Correctional Health
Grievance Nurse McNair, Correctional Health
Quality Manager Brown, Correctional Health
Program Manager Hamilton, Correctional Health

II. Mission Statement

The Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Invocation

Rev. Dr. Jeffrey Moore offered an invocation at the beginning of the meeting.

IV. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

V. Conflicts of Interest

After reviewing the agenda, the Chair noted there were no conflicts of interest on the agenda.

II. **Consent Agenda: Minutes**

A. Consideration and Appropriate Action Regarding
Minutes 2025-10-08 Audit Committee

B. Consideration and Appropriate Action Regarding
Minutes 2025-10-22 Facilities Committee

C. Consideration and Appropriate Action Regarding
Minutes 2025-10-28 Budget & Finance Committee

D. Consideration and Appropriate Action Regarding
Minutes 2025-10-29 Quality of Care & Patient Safety Committee

E. Consideration and Appropriate Action Regarding
Minutes 2025-10-29 Board of Managers

III. **Consent Agenda: Contracts**

A. Consideration and Appropriate Action Regarding Contracts over $200,000 **(See Attached List of Contracts)**

IV. **Consent Agenda: Capital Substitution(s)**

A. Consideration and Appropriate Action Regarding Capital Substitution(s) **(See Attached List of Capital Substitution(s))**

V. **Consent Agenda: Policies**

A. Consideration and Appropriate Action Regarding Presentation of Proposed Changes to Parkland Policy SYS.COMP.039, Reporting Obligations

VI. **Consent Agenda: Other**

A. Consideration and Appropriate Action Regarding Investment Committee Recommendation Regarding Investment Manager for Real Estate in the Pension Plan

B. Consideration and Appropriate Action Regarding the Delegation of Signature Authority for Certain Matters to Brad Nitschke, JD

VII. **Consent Agenda: Medical Executive Committee Items**

A. Consideration and Appropriate Action Regarding Medical Staff Bylaws

B. Consideration and Appropriate Action Regarding Board Resolution: Maternal Levels of Care Plan Program - 2026

C. Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff

Status Changes of the Medical Staff and Non-Physician Clinical Providers

Marjorie Petty asked if any items need to be pulled from the consent agenda for further discussion. None were removed. Marjorie asked for a motion to approve the consent agenda. Yasmin Simon motioned for approval of the consent agenda. Farida Minner seconded. The motion carried unanimously.

I. Reports Requiring Deliberation(s) or Approval(s)

A. Recognition Regarding Parkland Correctional Health

Marjorie Petty dedicated this Board meeting to acknowledge Parkland's Correctional Health Program and its vital role in serving the Dallas community. The recognition highlighted the collaborative partnerships between Parkland, law enforcement, and community organizations that support care for incarcerated individuals and facilitate smooth transitions back into the community. Special emphasis was placed on the nursing team's contributions, which were noted in Parkland's Magnet distinction, underscoring their exemplary work in correctional health. The board expressed pride and gratitude for the program's impact and strong partnerships.

Commissioner Price addressed the Parkland board to express gratitude and highlight key issues related to correctional health and jail operations. Commissioner Price emphasized compliance and management challenges, noting the scale of the jail, which serves 22,000 meals daily and includes a 300-bed hospital. He praised Parkland's team for their dedication, citing achievements such as a major operational transition and record prescription volumes. Price also thanked the board for accelerating the COPC project in the Inland Port area, recently approved by the Dallas County Commissioners Court, underscoring its importance for community access and service expansion.

Reports Requiring Deliberation(s) and/or Possible Action Cont.

A. Consideration and Appropriate Action Regarding Parkland Health Board Audit Committee Charter
B. Consideration and Appropriate Action Regarding Parkland Health Board Budget and Finance Committee Charter
C. Consideration and Appropriate Action Regarding Parkland Health Facilities Committee Charter
D. Consideration and Appropriate Action Regarding Parkland Health Board Governance Compliance and Ethics Committee Charter

E. Consideration and Appropriate Action Regarding Parkland Health Board Quality of Care & Patient Safety Committee Charter
F. Consideration and Appropriate Action Regarding Parkland Health Board Talent Development and Executive Compensation Committee Charter

Marjorie asked for a motion to approve the Committee Charters which are reviewed annually by the Board. Todd Furniss motioned for approval. Ramon Miguez seconded the motion. The motion passed unanimously.

B. Update and Report by Chief Executive Officer Regarding Operational Performance and Plans

Dr. Fred Cerise introduced Francesco Mainetti to the Board and asked him to provide an update regarding what is being done to reduce waiting times in our community clinics. Francesco outlined initiatives that significantly reduced wait times across clinics, with most now under 90 days for new adult patients. He explained that improvements were driven by three key areas: governance, processes and tools, and resource allocation. Strategies included optimizing scheduling templates, standardizing provider expectations, and offering patients alternative clinic locations to balance demand. These changes ensured better utilization of capacity and improved access system wide.

Additionally, Francesco highlighted resource adjustments such as repurposing county funds to support Saturday clinics, converting underutilized HIV providers into hybrid roles, and implementing flexible staffing models. Governance enhancements included regular leadership meetings, new policies to reduce no-show rates, and stricter controls on schedule management. He emphasized that these efforts, combined with patient education and robust appointment reminders, led to record-low no-show rates and improved patient satisfaction without adding staff. Future goals focus on expanding physical capacity, leveraging technology, and risk stratification to sustain progress.

The Board asked additional questions regarding Parkland COPCs and received further information from Francesco.

C. Board of Managers FY25 Conflict of Interest Annual Disclosures and Management Plans

Roshan Thayil reviewed Parkland's conflict of interest policy requirements, including updates following the recent accreditation survey. Question six was highlighted as a new addition, and the team explained how disclosures are gathered from multiple sources—formal statements, verbal disclosures, and public information—to ensure comprehensive reporting. A summary of affirmative responses from board members was shared, along with a breakdown of individual disclosures.

Most disclosures remained unchanged, except for one update involving a board member's new leadership role. Management plans for board members and executives were discussed,

with several plans pending review by the designated work group. The investment committee reported only one affirmative disclosure, which did not require a management plan. The session emphasized transparency and encouraged open communication with the compliance department for any questions or concerns.

D. Consideration and Appropriate Action Regarding the 2025 Community Health Needs Assessment (CHNA)

Teresita Oaks presented the 2025 Community Health Needs Assessment (CHNA), emphasizing its role in guiding strategic planning and meeting Affordable Care Act and public health accreditation requirements. The CHNA, conducted every three years in partnership with Dallas County Health and Human Services, utilized 21 quantitative data sources and community input through surveys and focus groups. Over 1,400 survey responses and 321 focus group participants provided insights into health priorities and social determinants. Positive trends included improved median income and internet connectivity, while concerning findings showed rising mental health challenges, particularly depression and anxiety, across 60 of 93 zip codes. Chronic diseases such as diabetes, heart disease, and cancer remain prevalent, though targeted efforts have reduced diabetes rates in four high-risk zip codes.

Community feedback highlighted five key dimensions of access—acceptability, availability, accommodation, affordability, and accessibility—with trust and patient experience emerging as critical factors influencing care continuity. Transportation barriers and long wait times were noted, along with a desire for one-stop health services, mobile clinics, and expanded virtual care. Affordability concerns centered on fear of medical debt and lack of price transparency. Additional priorities include maternal and child health, HIV prevention, and systemic alignment to reduce policy-related delays. Oaks requested board acceptance of the CHNA findings to proceed with the 2026–2028 implementation plan, which will align with strategic initiatives and leverage granular data for targeted outreach. The board acknowledged the extensive work and discussed adding an open comment section to the final report for community feedback.

Marjorie asked for a motion to accept the CHNA Report Findings and therefore move forward with the implementation planning. Todd Furniss motioned for approval. Byron Cryer seconded the motion. The motion passed unanimously.

E. Governance Update and Discussion Regarding Key Upcoming Dates and the Board Self-Assessment

Morgan Simmons and Saul Cordero reminded the Board of the annual Board Self-Assessment conducted in partnership with The Governance Institute. Responses are needed by the end of next week.

Break

II. Executive Session

At 2:55 PM, the Board went into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics, as necessary.

A. Consultation with Attorney Regarding Legal Risk and Vulnerability Assessment Due to Recent Changes in Federal Regulations and Executive Orders *Tex. Gov't Code §551.071*
B. Performance Appraisal Discussion: CEO and Board Dual Reports *Tex. Gov't Code §551.074*

Chair adjourned Executive Session and moved into Open Session at 4:48 PM.

III. Action Items

A. Board May Take Action on Any Agenda Item(s) Above

IV. Adjourn

With no further business to discuss, the Chair adjourned the meeting at 4:48 PM.

SO RECORDED:

Marjorie D. Petty, JD Chair	Todd Furniss, JD Secretary

Appendix A (Contracts Reviewed for Appropriate Action)

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
												November 19, 2025
Medical Products and Services												
M1	Expense	Mod # 3 Intraocular Lenses and Hydrus Microstents	Alcon Vision, LLC	11/14/2021-12/31/2027	$2,010,000	$5,146,180	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Perioperative Services	N/A	N/A	N/A
M2	Expense	Venaseal & ClosureFast Products	Medtronic USA, Inc.	12/24/2025 – 12/23/2030	$985,000	$985,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shawn Grady/Interventional Radiology	N/A	N/A	N/A
M3	Expense	Mod # 1 Omni Surgical System	Sight Sciences, Inc	5/25/2022-5/24/2026	$150,000	$444,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	David Alexander/Ambulatory Service Center	N/A	N/A	N/A
M4	Expense	Mod # 1 Hospice Care Services	Forefront Living Hospice, Pathway Hospice, LLC. & The Visiting Nurse Association of Texas	7/1/2024 -6/30/2029	$2,600,000	$3,550,000	Non-Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shannan Bradley/Care Management Post Acute Services	0%	N/A	N/A
M5	Expense	Mod # 6 add funding and extend agreement through November 30, 2028	Premier Radiology Services, LLC	8/1/2020 -11/30/2028	$2,211,023	$4,111,438	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Tina Hill/ Crystal Harrison/Correctional Health/ Radiology	N/A	N/A	N/A
Construction and Facilities												
C1	Expense: Court Approval	Contract to Purchase 5415 Gregg Steet, ±0.5051 acres of land, Dallas, Texas	Gregg Street, LLC	Upon contact execution – plus 150 days for inspection & closing	$2,000,000	$2,000,000	Real Estate – Exemption	Yes	Beall Carothers/Planning Design & Construction	N/A	N/A	N/A
Information Technology												
IT1	Expense	Mod # 1 Add Web Hosting and Direct Data Configuration Services	Wellsky Corporation	11/21/2017-11/18/2030	$828,960	$4,241,047	Sole Source Modification	Yes	Greggory Ervin / LeMar Oleson/Information Technology	N/A	N/A	N/A

Parkland Health
FY2026 Capital Substitution
For November 2025 Board Meeting

Ref #	Division	Project Total	Substitution Amount	Description
1	COPC/Ambulatory Specialty Clinics	$1,455,420	$1,036,920	Bluitt Flowers COPC Renovation/Optimization and Clinic Relocations
	Explanation	This project request includes the renovation of the Bluitt Flowers COPC, clinic relocations, and the optimization of space at other COPC locations in the southern region. This request will provide additional space for patient care activities, allow the expansion of specialty care in the community, and provide access to onsite pediatric behavioral health services at the CV Roman COPC. Also, two clinics will be combined, which will improve managerial oversight and reduce lease expenses. This request seeks approval to utilize funds that were previously budgeted for other projects at Bluitt Flowers and CV Roman. No renovations have been made to the CV Roman Clinic. The timing of those meeting with key stakeholders occurred after the budget submission. During discussions regarding the implementation of the original CV Roman project, leaders from operations, nursing, and the physician group all agreed that utilizing the funds for the Bluitt Flowers & CV Roman renovations would yield a better return on investment. This request has been briefed by the facilities committee. The relocation and consolidation of services will improve patient experience by moving to locations that are located on the DART bus routes, easier access to clinic locations and additional services out in the community. The original budget request for the Bluitt Flowers renovation project was to convert business office space to clinical space, which would have created three exam rooms, one provider office, and one storage closet. The revised request will create three exam rooms, one consultation room, and six staff workstations in a pod that will be used for specialty care. Also, a nurse station will be added to include five cubicles and one office. The renovation will also include the reconfiguration of the IT room to minimize any potential life safety issues. To optimize space, there will also be several clinic relocations. Specialty services will move from CV Roman to Bluitt Flowers and allow OPC to expand services in the community. Pediatrics will move from Oak West to CV Roman and will provide access to onsite pediatric behavioral services. The CV Roman and Wynnewood ARCs will both move to Oak West and will be combined. This will improve managerial oversight and reduce lease expenses.	
	Driver(s) of Increased Expense:	Additional renovation at Bluitt Flowers; clinic relocations to optimize space;		
	Description of Item:	Bluitt Flowers Clinic renovation; clinic relocations		
	Grand Total	**$1,455,420**	**$1,036,920**	

Consideration and Appropriate Action Regarding Contracts over $200,000

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.
December 17, 2025									
Medical Products and Services									
M1	Capital	Walk-Away Specimen Processor (WASP) and Accessories	Beckman & Coulter, Inc.	Last Signature – 12/4/2026	$365,302	$365,302	GPO Purchase	Yes	Bernie Buenvenida/Clinical Engineering
M2	Expense	Mod # 10 Medtronic Neuro Interventional Products	Medtronic USA, Inc.	10/24/2018 - 12/31/2027	$406,000	$2,641,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shawn Grady/Interventional Radiology
M3	Expense	Mod # 8 Microvention Neuro Interventional Products	Microvention, Inc.	7/1/2019 -12/31/2027	$730,000	$3,567,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Shawn Grady/Interventional Radiology
M4	Expense	Mod # Streck Laboratories BCT Tubes	Streck Laboratories	1/1/2024 -12/31/2026	$400,000	$800,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristian Faulk/Scott Hampton/Laboratory Services - Chemistry
M5	Capital and Expense	Purchase of the Solventum V.A.C Ulta Negative Pressure Wound Therapy units.	Solventum	12/17/2025 – 5/19/2026	$729,612	$729,612	GPO Purchase	Yes	Pamela Bryant/Supply Chain
Construction and Facilities									

C1	Capital	Mod # 1 Additional Service #5	Corgan Associates, Inc.	8/31/2023 -6/11/2027	$42,475	$1,115,405	Non-Sole Source Modification	Yes	Paul Woodard/Planning Design and Construction
C2	Expense: Court Approval	Mod # 1 First Amendment to Office Lease Agreement	Homeward Bound, Inc.	6/1/2022-5/31/2030	$0	$0	Sole Source Modification	N/A-Zero Dollar	Beall Carothers/Planning Design & Construction
				Hospital Operations					
O1	Expense	Telephone Answering Services	New Orleans Teleport dba Calls Plus	4/2/2026 – 4/1/2031	$447,000	$447,000	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Prentiss Wright/Call Center Operations
O2	Revenue	Mod #8 MIPS/TIPPS Reporting Services (Revenue)	The University of Texas Southwestern Medical Center	3/9/2022-9/30/2026	($374,841)	($2,121,231)	Contract Extension without Competition	N/A-Revenue	Keri Disney-Story/Finance Administration
O3	Expense	Mobile Medical Clinic	Farber Specialty Vehicle	12/18/2025 – 12/17/2026	$732,737	$732,737	Sole Source	Yes	Kyla Rankin/Homes
O4	Expense	Childcare Operations Provider	Learning Care Group	1/1/2026 – 12/31/2030	$1,061,827	$1,061,827	Request for Proposals (Best Value)	Yes	Ryan Alcantar & Miranda Bond/Office of Talent Management

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: December 17, 2025	**Product or Service:** Walk-Away Specimen Processor (WASP) and Accessories	
Business Owner: Bernie Buenvenida	**Business Owner Dept:** Clinical Engineering	**Contract Number:** POCP-25829
Vendor/Supplier/Contractor: Beckman & Coulter, Inc.	**Source Selection Methodology:** GPO Purchase	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital

	Contract Dates	Contract Price
Base Term:	Last Signature – 12/4/2026	$365,302
Out Years:	0 Year(s)	+$0
Total:	Last Signature – 12/4/2026	$365,302

Lowest Bidder

Is this contractor the lowest bidder/supplier? GPO Purchase

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes

FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.

Were M/WBE's Directly Solicited? N/A-no solicitation performed

Number Responding M/WBE's: N/A-no solicitation performed

What % of this contract is M/WBE? N/A

M/WBE Race/Ethnicity? N/A

M/WBE Gender? N/A

Submitted By (Division VP): Lance Mendiola, Vice President, Construction, Facilities, Real Estate

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Walk-Away Specimen Processor (WASP) and Accessories

VENDOR: Beckman & Coulter, Inc.

COST:		
	Base Term:	$365,302
	Out Years:	+ $0
	Total:	$365,302

Recommendation
Approve this contract for Walk-Away Specimen Processor (WASP) and Accessories.

Background
This contract is for the purchase of a WASP® (Walk-Away Specimen Processor) lab analyzer to replace an existing one which will no longer be supported as of January 2026. The WASP® is a modular, open platform lab analyzer that fully automates all facets of specimen processing, freeing technologists from labor-intensive manual tasks and allowing them to focus on high-complexity work**.** This is for the Microbiology Lab.

Fair and Reasonable Price Determination
The GPO contract and pricing was obtained in a solicitation process performed by Vizient. Market research conducted through ECRI shows that Parkland price is average compared to other hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2026
Equipment / Licenses	$365,302

Document Contact/Author:	Andrew Barter

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: December 17, 2025	**Modification:** Mod # 10 Medtronic Neuro Interventional Products	
Business Owner: Shawn Grady	**Business Owner Dept:** Interventional Radiology	**Contract Number:** POCP-19594 A8
Vendor/Supplier: Medtronic USA, Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (12/18/2024): Actions Totaling < $100,000 Amount: Amount: Amount:	$2,235,000
Revenue, Expense or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 10 Amount:	$406,000
Original Start Date: 10/24/2018 **Current Expiration:** 12/31/2025 **Mod Start Date:** Last Signature **Expiration after this Mod:** 12/31/2027	New Contract Amount:	$2,641,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	N/A
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 10 Medtronic Neuro Interventional Products

VENDOR: Medtronic USA, Inc.

COST:

BOM Approved Contract Total (12/18/2024):	$2,235,000
Action:	
Action:	
Action:	
Modification # 10:	+ $406,000
Total:	$2,641,000

Recommendation
Approve this contract modification to Medtronic Neuro Interventional Products.

Background
This contract is for the purchase of Medtronic Neuro Interventional products. Coils and accessories are used in the treatment of acute stroke patients in Interventional Radiology procedures. These products are used to remove blood clots and control bleeding in the brain for patients whose clinical pathology and anatomy are compatible to the design strengths of these products.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 3% lower than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2026	FY2027	FY2028	Total
$2,235,000	$152,250	$203,000	$50,750	$2,641,000

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	William Jones

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: December 17, 2025	**Modification:** Mod # 8 Microvention Neuro Interventional Products	
Business Owner: Shawn Grady	**Business Owner Dept:** Interventional Radiology	**Contract Number:** POCP-19397 A7
Vendor/Supplier: Microvention, Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (8/28/2024): Actions Totaling < $100,000 Amount: Amount: Amount:	$2,837,000
Revenue, Expense or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 8 Amount:	$730,000
Original Start Date: 7/1/2019 **Current Expiration:** 12/31/2025 **Mod Start Date:** Last Signature **Expiration after this Mod:** 12/31/2027	New Contract Amount:	$3,567,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	N/A
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 8 Microvention Neuro Interventional Products

VENDOR: Microvention, Inc.

COST:

BOM Approved Contract Total (8/28/2024):	$2,837,000
Action:	
Action:	
Action:	
Modification # 8:	+ $730,000
Total:	$3,567,000

Recommendation
Approve this contract modification to Microvention Neuro Interventional Products.

Background
This contract is for the purchase of Microvention Neuro Interventional products. This contract is to purchase coils and accessories. They are used in the treatment of acute stroke. These products are used to remove blood clots and control bleeding in the brain for patients whose clinical pathology and anatomy are compatible to the design strengths of these products.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 4% lower than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2026	FY2027	FY2028	Total
$2,837,000	$273,750	$365,000	$91,250	$3,567,000

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	William Jones

Board Approval Request For Modification to Contract or Funding

BOM Date: December 17, 2025	**Modification:** Mod # Streck Laboratories BCT Tubes	
Business Owner: Kristian Faulk/Scott Hampton	**Business Owner Dept:** Laboratory Services - Chemistry	**Contract Number:** PO 10378
Vendor/Supplier: Streck Laboratories **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Previous Board Approved Amount (12/18/2025):	$400,000
	Total amount of actions since last approval	$0
Revenue, Expense or Capital: Expense	Current amount requested:	$400,000
Original Start Date: 1/1/2024 **Last BOM Approval Date:** 12/18/2024 **Current Expiration:** 12/31/2025 **Mod Start Date:** 1/1/2026 **Expiration after this Mod:** 12/31/2026	New Board Approved Amount:	$800,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Legal approved base document, amendment has no changes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	N/A
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # Streck Laboratories BCT Tubes

VENDOR: Streck Laboratories

COST:

Previous Board Approved Amount (12/18/2025):	$400,000
Actions since last approval	$0
Board amount requested :	+ $400,000
Total:	$800,000

Recommendation

Approve this contract modification to Streck Laboratories BCT Tubes.

Background

This contract is for the annual quote for the cell-free DNA (cfDNA) BCT specimen tubes that are used for our Vanadis equipment owned by the Parkland lab. These specimen tubes are designed specifically for testing on the Vanadis cfDNA Platform, and no other tubes can be used. The Parkland lab is in the process of acquiring an additional Vanadis system. With the increased usage expected due to the new equipment and the current equipment still being fairly new, funding will also be increased accordingly.

Fair and Reasonable Price Determination

Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland pricing ranges between the 25th percentile and median pricing. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2026	FY2027	Total
$400,000	$300,000	$100,000	$800,000

Sole Source Justification

The compatibility of equipment, accessories, or replacement parts is the paramount consideration, and there is no assurance that other supplies will perform the same function, including additions or modifications to existing systems, software, licenses, maintenance, etc. Specimen tubes are designed specifically for testing on the Vanadis cfDNA Platform, and no other tube can be used.

Document Contact/Author:	Tamisha Smallwood

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: December 17, 2025	**Product or Service:** Purchase of 26 Solventum V.A.C Ulta Negative Pressure Wound Therapy units.	
Business Owner: Pamela Bryant	**Business Owner Dept:** Supply Chain	**Contract Number:** PO# 2259654-CAP
Vendor/Supplier/Contractor: Solventum	**Source Selection Methodology:** GPO Purchase	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital and Expense

	Contract Dates	Contract Price
Base Term:	12/17/2025 – 5/19/2026	$729,612
Out Years:	0 Year(s)	+$0
Total:	12/17/2025 – 5/19/2026	$729,612

Lowest Bidder

Is this contractor the lowest bidder/supplier? GPO Purchase

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes

FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, but supplier diversity received their corporate plan.

Were M/WBE's Directly Solicited? N/A-no solicitation performed

Number Responding M/WBE's: N/A-no solicitation performed

What % of this contract is M/WBE? N/A

M/WBE Race/Ethnicity? N/A

M/WBE Gender? N/A

Submitted By (Division VP): Pam Bryant, Senior Vice President, Chief Supply Chain Officer

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Purchase of 26 Solventum V.A.C Ulta Negative Pressure Wound Therapy units.

VENDOR: Solventum

COST:		
	Base Term:	$729,612
	Out Years:	+ $0
	Total:	$729,612

Recommendation
Approve this purchase PO for Purchase of 26 Solventum V.A.C Ulta Negative Pressure Wound Therapy units..

Background
Parkland originally entered into a rental agreement with KCI for their V.A.C. Ulta Negative Pressure Wound Therapy units. While there was interest in purchasing more units, KCI was only able to accommodate rental arrangements at that time. KCI has since been sold and formed a new company, Solventum, which now allows Parkland to purchase these VACs. The price of rented units exceeds $1K/month for each unit. This purchase aligns with Parkland's fiscal goals as these are 10-year depreciable assets and are usually in use for 12 years. This one-time capital purchase represents an 80% savings compared to leasing for the useful life or the vacs.

Fair and Reasonable Price Determination
The GPO contract and pricing was obtained in a competitive solicitation process performed by Vizient. The District's negotiated rate is 29% below the competitively solicited GPO Price

Financial Forecast

Base Term	FY2026
Expenses / Consumables	$729,612

Document Contact/Author:	Karen Robins

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: December 17, 2025	**Modification:** Mod # 1 Additional Service #5	
Business Owner: Paul Woodard	**Business Owner Dept:** Planning Design and Construction	**Contract Number:** PONCS-23182
Vendor/Supplier: Corgan Associates, Inc. **Basis of Original Contract Award** Request for Proposals (Low Price/Tech Accept) **Basis of this Modification** Non-Sole Source Modification	BOM Approved Contract Total (8/31/2023)	$983,330
	Actions Totaling > $100,000 Amount:	$89,600
Revenue, Expense or Capital: Capital	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 1 Amount:	$42,475
Original Start Date: 8/31/2023 **Current Expiration:** 11/30/2025 **Mod Start Date:** Last signature **Expiration after this Mod:** 6/11/2027	New Contract Amount:	$1,115,405

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes
FTE Impact:	None

Diversity

Current M/WBE Participation?	35%
M/WBE Race/Ethnicity?	See Chart
M/WBE Gender?	See Chart

Submitted By (Division VP): Lance Mendiola, Vice President of Construction, Facilities, Real Estate, Operations Administration

SUBJECT: Mod # 1 Additional Service #5

VENDOR: Corgan Associates, Inc.

COST:		
	BOM Approved Contract Total (8/31/2023)	$983,330
	Action:	$89,600
	Action:	
	Action:	
	Modification # 1:	+ $42,475
	Total:	$1,115,405

Recommendation
Approve this contract modification to Additional Service #5.

Background
This contract is for the design services of the Vickery Clinic outpatient building which is to be located on the Richland College Campus in Northeast Dallas.

This supplemental agreement is needed to formally document the project's value engineering revisions. Plan changes, requested by clinic staff, which produce a minor modification to the Patient Financial Services Department, and which include the addition of an exam room in the Women's Infant's Specialty Health Department, are included. The additional fees required to make these design changes fall well within the anticipated Architecture & Engineering budget. A previous Amendment was processed for $89,600 and did not require BOM approval. The value of this new supplemental agreement, when combined with the previous Change Order, exceeds the $100k threshold.

Fair and Reasonable Price Determination

A fair and reasonable price for the whole project's design was determined through Request for Qualifications which was sent out to over 900 vendors. Parkland received 14 responses which were evaluated resulting in presentations from the top two vendors. Modification #1 from the successful vendor includes drawing changes documenting the value engineering revision required to establish the construction Guaranteed Maximum Price, and included in this additional services request #5 are the drawing revisions for the Patient Financial Services and the Women's Infant Specialty Health Department. These fees were the subject of fee submission by the vendor and negotiation with the vendor. These additional fees fall well within the anticipated Architecture & Engineering budget.

Financial Forecast

Current Contract Amount	FY2025	FY2026	Total
$983,330	$89,600	$42,475	$1,115,405

Document Contact/Author:	Farrah Smith

Board Approval Request For Modification to Contract or Funding

BOM Date: December 17, 2025	**Modification:** Mod # 1 First Amendment to Office Lease Agreement	
Business Owner: Beall Carothers	**Business Owner Dept:** Planning Design & Construction	**Contract Number:** POCRE-20456.1
Vendor/Supplier: Homeward Bound, Inc. **Basis of Original Contract Award** Real Estate – Exemption **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (11/16/2021):	$0
Revenue, Expense or Capital: Expense: Court Approval	Modification # 1 Amount:	$0
Original Start Date: 6/1/2022 **Current Expiration:** 5/31/2025 **Mod Start Date:** 6/1/2025 **Expiration after this Mod:** 5/31/2030	New Contract Amount:	$0

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	N/A-Zero Dollar
FTE Impact:	None

Diversity

Current M/WBE Participation?	N/A
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Lance Mendiola, Vice President of Construction, Facilities, Real Estate, Operations Administration

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 1 First Amendment to Office Lease Agreement

VENDOR: Homeward Bound, Inc.

COST:

BOM Approved Contract Total (11/16/2021):	$0
Modification # 1:	+ $0
Total:	$0

Recommendation
Approve this contract modification to First Amendment to Office Lease Agreement.

Background
Dallas Deflects is a collaboration between Homeward Bound, Inc., NTHBA, Parkland, and Dallas County District Attorney's office. The intent of Dallas Deflects is to serve as a diversion center for individuals with low-level, non-violent misdemeanors and a primary care clinic site for all individuals receiving services at Homeward Bound. The site creates increased access to care for homeless patients, strengthen relationships with community partners serving the homeless community and has created a new referral site for discharged Emergency Department patients. Within the site, Parkland operates primary care services one to two days per week in which a three-person team provides medical visits for the residents at Homeward Bound. Additionally, HOMES provides registered nurse intake for the Deflection Center seven days per week. During these times, the HOMES registered nurse provides intake (based on protocol) for the individuals who are brought into the Deflection Center.

Fair and Reasonable Price Determination
N/A – Real Estate Exemption

Financial Forecast

Current Contract Amount	FY2026	FY2027	FY2028	FY2029	FY2030	Total
$0	$0	$0	$0	$0	$0	$0

Sole Source Justification
NA – Real Estate Exemption

Document Contact/Author:	Beall Carothers, Director Real Estate Development

Board Approval Request For Contracts Over $200,000

BOM Date: December 17, 2025	**Product or Service:** Telephone Answering Services	
Business Owner: Prentiss Wright	**Business Owner Dept:** Call Center Operations	**Contract Number:** PONCS-25387
Vendor/Supplier/Contractor: New Orleans Teleport dba Calls Plus	**Source Selection Methodology:** Request for Proposals (Best Value)	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	4/2/2026 – 4/2/2029	$268,200
Out Years:	2 Year(s)	+178,800
Total:	4/2/2026 – 4/1/2031	$447,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? Yes

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

FTE Impact: None

Diversity

Potential for M/WBE engagement: This award is to a M/WBE vendor.

Were M/WBE's Directly Solicited? Yes

Number Responding M/WBE's: 6

What % of this contract is M/WBE? 100%

M/WBE Race/Ethnicity? Black or African American

M/WBE Gender? Female

Submitted By (Division VP): Francesco Mainetti, Senior Vice President Transformational Initiative, Operations Administration

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Telephone Answering Services

VENDOR: New Orleans Teleport dba Calls Plus

COST:		
	Base Term:	$268,200
	Out Years:	+ 178,800
	Total:	$447,000

Recommendation
Approve this contract for Telephone Answering Services.

Background

This contract is for the procurement of Telephone Answering Services to support the District's healthcare operations. The selected vendor will provide bilingual (English and Spanish) Health Service Representatives who will professionally answer incoming calls, relay messages to physicians accurately and promptly, and adhere to specific protocols and guidelines established by the District. These services are essential to ensure consistent, high-quality communication between patients and healthcare providers. The contract will primarily serve the needs of Call Center Operations, enhancing accessibility and responsiveness for our diverse patient population. The incumbent vendor, New Orleans Teleport dba Calls Plus, has provided outsourced services since 2017, handling about 600 bilingual patient calls each month. These calls are routed to Parkland on-call providers after 5:00 p.m. on weekdays, as well as on weekends and holidays, they previously offered the same scope of service.

Fair and Reasonable Price Determination

Market research conducted through ECRI shows that the Parkland price is average compared to other member hospitals. New Orleans Teleport, the incumbent, earned the highest technical score out of 100. Best Value was determined through a cost/technical trade-off considering price and non-price factors.

Competitive Range				
Vendor	**Key Strengths**	**Key Weaknesses**	**Non-Cost Score**	**Price Differential**
New Orleans Teleport	The vendor provided detailed experience examples in Schedule C of the Statement of Work.		60	$0
Vendor B		Program management and project team seem minimal.	59	+ $524,000
Vendor C		Program management and project team seem minimal.	59	+ $509,000
Vendor D		All responsibility references point to Dat DocScan, not Lee's Consulting.	57	+ $187,000

Financial Forecast

Base Term	FY2027	FY2028	FY2029	FY2030	FY2031	Total
Expenses	$89,400	$89,400	$89,400			$268,200
Out Years	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**FY2031**	**Total**
Expenses				$89,400	$89,400	$178,800
Grand Totals	**$89,400**	**$89,400**	**$89,400**	**$89,400**	**$89,400**	**$447,000**

Document Contact/Author:	Adrian Baltimore

Board Approval Request For Modification to Contract or Funding

BOM Date: December 17, 2025	**Modification:** Mod # 8 MIPS/TIPPS Reporting Services (Revenue)	
Business Owner: Keri Disney-Story	**Business Owner Dept:** Finance Administration	**Contract Number:** POCS-20728 A5
Vendor/Supplier: The University of Texas Southwestern Medical Center **Basis of Original Contract Award** N/A-Revenue **Basis of this Modification** Contract Extension without Competition	BOM Approved Contract Total (10/30/2024):	($1,746,390)
	Actions Totaling < $100,000 Amount: Amount: Amount:	
Revenue, Expense or Capital: Revenue	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 8 Amount:	($374,841)
Original Start Date: 3/9/2022 **Current Expiration:** 8/31/2025 **Mod Start Date:** 9/1/2025 **Expiration after this Mod:** 9/30/2026	New Contract Amount:	($2,121,231)

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	N/A-Revenue
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Keri Disney-Story, SVP Finance Administration

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 8 MIPS/TIPPS Reporting Services (Revenue)

VENDOR: The University of Texas Southwestern Medical Center

COST:

BOM Approved Contract Total (10/30/2024):	($1,746,390)
Action:	
Action:	
Action:	
Modification # 8:	+ ($374,841)
Total:	($2,121,231)

Recommendation

Approve this contract modification to MIPS/TIPPS Reporting Services (Revenue) .

Background

Under this contract, our Government Reimbursement Team provides certain services and data to UT Southwestern Medical Center for obligatory CMS MIPS and TIPPS reporting. The data is then used by CMS to determine scores, which determine payment adjustments applied to Medicare Part B claims. This contract was originally slated to roll into the UT Southwestern Medical Center Master Services Agreement ("MSA") in fiscal year 2026 but was later decided by our Legal teams to keep it separate. No expenses have been incurred during the first 3 months of this contract. Expenses specific to UT Southwestern Medical Center under this contract do not incur until January 2026.

Fair and Reasonable Price Determination

Our revenue amounts are determined to be fair and reasonable by our Government Reimbursement Department based on actual amounts spent to provide these services and historical work.

Financial Forecast

Current Contract Amount	FY2025	FY2026	Total
($1,746,390)	($28,834)	($346,007)	($2,121,231)

Exempt from Competition Justification

Contracts between two governmental agencies are exempt from competition.

Document Contact/Author:	Stephanie Toth

Board Approval Request For Contracts Over $200,000

BOM Date: December 17, 2025	**Product or Service:** Mobile Medical Clinic	
Business Owner: Kyla Rankin	**Business Owner Dept:** Homes	**Contract Number:** PONCP-25958
Vendor/Supplier/Contractor: Farber Specialty Vehicle	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Market Price

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	12/18/2025 – 12/17/2026	$732,737
Out Years:	0 Year(s)	+0
Total:	12/18/2025 – 12/17/2026	$732,737

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? No
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, but supplier diversity received their corporate plan.
Were M/WBE's Directly Solicited? N/A-no solicitation performed
Number Responding M/WBE's: N/A-no solicitation performed
What % of this contract is M/WBE? N/A
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Pam Bryant, Senior Vice President, Chief Supply Chain Officer

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mobile Medical Clinic

VENDOR: Farber Specialty Vehicle

COST:		
	Base Term:	$732,737
	Out Years:	+ 0
	Total:	$732,737

Recommendation
Approve this contract for Mobile Medical Clinic.

Background

This contract is to purchase a new mobile medical unit to support HOMES Primary Care, utilizing a combination of Health Resources and Services Administration (HRSA) grant funds and Parkland Foundation funds.

The mobile medical unit will be a replacement unit in the existing fleet and serve areas identified within HOMES HRSA service sites.

The mobile unit will service existing community partners and any potential new community partners. Estimated final delivery is August 2026.

HOMES currently has 6 mobile units in the HOMES fleet, this new unit will replace an aging unit that will be retired from the fleet.

Fair and Reasonable Price Determination
Due to the custom nature of the vehicle, it is impossible to achieve a direct costs analysis, however, the pricing paid by the District is consistent with prior purchases of the previous vehicle.

Financial Forecast

Base Term	FY2025
Equipment / Licenses	$732,737

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to a custom vehicle fleet specific to a single vendor.

Grant Expenses
This purchase is Parkland Foundation funded.

Document Contact/Author:	Adrian Baltimore

Parkland

Board Approval Request
For Contracts Over $200,000

BOM Date: December 17, 2025	**Product or Service:** Childcare Operations Provider	
Business Owner: Ryan Alcantar & Miranda Bond	**Business Owner Dept:** Office of Talent Management	**Contract Number:** PONCS-25549
Vendor/Supplier/Contractor: Learning Care Group	**Source Selection Methodology:** Request for Proposals (Best Value)	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	1/1/2026 – 12/31/2028	$618,180
Out Years:	2 Year(s)	+$443,647
Total:	1/1/2026 – 12/31/2030	$1,061,827

Lowest Bidder

Is this contractor the lowest bidder/supplier? Yes
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? In Process
Does this contract have an IT Component? No
Does this contract have a Construction Component? Yes; approval in process

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, but supplier diversity received their corporate plan.
Were M/WBE's Directly Solicited? Yes
Number Responding M/WBE's: 1
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Edmundo Castañeda, Executive Vice President & Chief Operating Officer

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Childcare Operations Provider

VENDOR: Learning Care Group

COST:		
	Base Term:	$618,180
	Out Years:	+ $443,647
	Total:	$1,061,827

Recommendation

Approve this contract for Childcare Operations Provider.

Background

This contract is for childcare operations provider. The selected provider will be responsible for staffing and managing a licensed childcare facility located within Parkland Health's premises. This early childhood care and education program will offer scheduled, full-time childcare for Parkland Health employees, along with backup and drop-in services available to both employees and patients. Serving children from 6 weeks to 10 years of age, the program will play a vital role in supporting the Parkland Health community.

Learning Care Group (LCG) brings a deep operational background dating back to the 1960s, with decades of proven experience in early childhood education. Today, LCG operates a network of more than 1,100 schools, serving children across 40 states. Its growth has been driven by both organic expansion and the strategic acquisition of regional providers. This depth of experience positions LCG as a partner for managing new builds, transitions, and complex environments including hospital campuses.

References provided by LCG and verified by the District include:

- Memorial Health Hospital in Marysville, OH
- Tarleton State University in Stephenville, TX
- Los Angeles International Airport (LAX), operated by Los Angeles World Airports (LAWA)

Fair and Reasonable Price Determination

A fair and reasonable price was determined through adequate competition.

Competitive Range				
Vendor	**Key Strengths**	**Key Weaknesses**	**Non-Cost Score**	**Price Differential**
Learning Care Group	Vendor cites experience working with healthcare institutions as well as other large public institutions (airport) with need for flexible care. This past experience suggest familiarity with the dynamic needs of Parkland's workforce and patient population.		71	$0

	Operates 1,100+ schools and located in over 40 states. Vendor cites a cost philosophy predicated on efficiency without compromising quality. The vendor notes that this balance is achieved through dynamic market analysis, leveraging federal and state subsidize programs, and dynamic staffing models. Vendor cites a corporate and investor structure that supports multi-site implementation and oversight; along with cost-optimization.			
Vendor B	Experience operating accredited, multi-site childcare centers. This includes launching sites as well as site-turnover. Delineated processes employed to address identified challenges with positive outcomes.	Vendor does not have much depth, nor any corporate central support. Vendor has no childcare services within hospital or healthcare operations.	68	$80,135
Vendor C	Vendor has a robust shared service infrastructure that supports childcare site launch, implementation, and quality control. Vendor has prior experience with health systems and demonstrates awareness of childcare as a workforce engagement tool.	Vendor did not provide a list of existing centers. Limited information provided regarding key staff members, including their qualifications, experience, position, and tenure with the organization.	67	$84,284
Vendor D		The vendor lacks experience in providing full-time childcare services during the workday and therefore has no direct expertise in the services currently required by the District. Vendor does not appear to have an established curriculum or a robust quality framework and has limited experience in achieving NAEYC accreditation or TRS star ratings.	59	$38,600

		Vendor has not operated at a scale comparable to Parkland Health's historic or anticipated volumes.		

Financial Forecast

Base Term	FY2026	FY2027	FY2028	FY2029	FY2030	FY2031	Totals
Expenses / Consumables	$150,000	$204,500	$210,635	$53,045			$618,180
Totals	$150,000	$204,500	$210,635	$53,045			$618,180
Out Years	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**FY2031**	**Totals**
Expenses / Consumables				$163,909	$223,463	$56,276	$443,647
Totals				$163,909	$223,463	$56,276	$443,647
Grand Totals	**$150,000**	**$204,500**	**$210,635**	**$216,954**	**$223,463**	**$56,276**	**$1,061,827**

Document Contact/Author:	Terence Durham

CONTRACT RESOLUTION
Board of Managers
December 17, 2025

PARKLAND HEALTH

RESOLUTION NO. _____

Be it resolved, the Parkland Health Board of Managers, by a vote of _____ Yes and _____ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS, Parkland Health management requested approval for certain contracts and approval/rejection is as checked below:

Approved	Rejected	Withdrawn	Type	Service or Product	Vendor	Contract Term	Aggregate Contract Amount Approved	Budgeted
			Capital	Walk-Away Specimen Processor (WASP) and Accessories	Beckman & Coulter, Inc.	Last Signature – 12/4/2026	$365,302	Yes
			Expense	Mod # 10 Medtronic Neuro Interventional Products	Medtronic USA, Inc.	10/24/2018 - 12/31/2027	$406,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 8 Microvention Neuro Interventional Products	Microvention, Inc.	7/1/2019 -12/31/2027	$730,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # Streck Laboratories BCT Tubes	Streck Laboratories	1/1/2024 -12/31/2026	$400,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Capital and Expense	Purchase of the Solventum V.A.C Ulta Negative Pressure Wound Therapy units.	Solventum	12/17/2025 – 5/19/2026	$729,612	Yes
			Capital	Mod # 1 Additional Service #5	Corgan Associates, Inc.	8/31/2023 -6/11/2027	$42,475	Yes
			Expense: Court Approval	Mod # 1 First Amendment to Office Lease Agreement	Homeward Bound, Inc.	6/1/2022-5/31/2030	$0	N/A-Zero Dollar
			Expense	Telephone Answering Services	New Orleans Teleport dba Calls Plu	4/2/2026 – 4/1/2031	$447,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Revenue	Mod #8 MIPS/TIPPS Reporting Services (Revenue)	The University of Texas Southweste	3/9/2022-9/30/2026	($374,841)	N/A-Revenue
			Expense	Mobile Medical Clinic	Farber Specialty Vehicle	12/18/2025 – 12/17/2026	$732,737	Yes
			Expense	Childcare Operations Provider	Learning Care Group	1/1/2026 – 12/31/2030	$1,061,827	Yes

THEREFORE, BE IT RESOLVED, that the Parkland Health Board of Managers approves these contracts as noted.

Dated this 17th of December 2025.

_____
Marjorie D. Petty, JD
Chair

_____
Todd Furniss, JD
Secretary

Marjorie Petty, JD	Yes _____	No _____	Abstain _____	Absent _____
Elizabeth Palacios, MD	Yes _____	No _____	Abstain _____	Absent _____
Todd Furniss, JD	Yes _____	No _____	Abstain _____	Absent _____
Eric G. Bing, MD, PhD	Yes _____	No _____	Abstain _____	Absent _____
Byron Cryer, MD	Yes _____	No _____	Abstain _____	Absent _____
Reina Gonzalez, JD	Yes _____	No _____	Abstain _____	Absent _____
Vincent Hall	Yes _____	No _____	Abstain _____	Absent _____

Ramon Miguez, PE	Yes _____	No _____	Abstain _____	Absent _____
Farida Minner, RN	Yes _____	No _____	Abstain _____	Absent _____
Lisa Sutter	Yes _____	No _____	Abstain _____	Absent _____
Yasmin Simon, JD	Yes _____	No _____	Abstain _____	Absent _____

Consideration and Appropriate Action Regarding Capital Substitution(s)

Parkland Health
FY2026 Capital Substitution
For December 2025 Board Meeting

Ref #	Division	Project Total	Substitution Amount	Description
1	Facilities and Perioperative Services	$3,648,128	$1,698,526	Facility Expansion and Equipment for Procedure Rooms at the Simmons Ambulatory Surgical Center (ASC)
	Explanation	The purpose of this capital request is to increase surgical procedures at the Simmons Ambulatory Surgical Center (ASC), which is located at the intersection of Medical District Drive and Harry Hines Blvd. Currently, there are two procedure rooms at the ASC that are being used for equipment storage. To optimize the patient care space and improve operations, a capital request to build 1,213 square feet of storage space was approved, which would allow the two procedure rooms to be utilized for patient care. A change in scope requires an increase to the capital budget. In the revised scope, the square feet for storage increased to 2,266 square feet based on the additional services that will be provided at the ASC and long term storage needs. The ASC is projected to continue operations at its current location for the next 20 years. Approval of this request will allow the opportunity to increase ophthalmic laser, pain, and coloscopy procedures. As services expand at the ASC, additional equipment will be required to support the expanded services and space will be needed to accommodate the additional medical equipment (i.e., colonoscopy equipment and surgical robots). As of 12/8/25, there are $21,377,965 available in contingency funds.		
	Driver(s) of Increased Expense:	Additional space to meet long term storage needs; colonoscopy equipment		
	Description of Item:	Storage space; colonoscopy equipment		
	Grand Total	**$3,648,128**	**$1,698,526**	

PARKLAND HEALTH

RESOLUTION NO. _____

Be it resolved, the Parkland Health Board of Managers, by a vote of _____ Yes and _____ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS, Parkland Health management requests approval for the use of contingency funds for capital items in the amount of $3,648,128 for FY25 as itemized in the listing presented to the Board of Managers, and

THEREFORE, BE IT RESOLVED, that the Parkland Health Board of Managers approves the use of funds as submitted.

Dated this ____th Day of _____2025.

_____ _____

Marjorie Petty, JD — Chair

Todd Furniss, JD — Secretary

Marjorie Petty, JD	Yes_____	No _____	Abstain _____	Absent _____
Elizabeth Palacios, MD	Yes_____	No _____	Abstain _____	Absent _____
Todd Furniss, JD	Yes_____	No _____	Abstain _____	Absent _____
Eric G. Bing, MD, PhD	Yes_____	No _____	Abstain _____	Absent _____
Byron Cryer, MD	Yes_____	No _____	Abstain _____	Absent _____
Reina Gonzalez, JD	Yes_____	No _____	Abstain _____	Absent _____
Vincent Hall	Yes_____	No _____	Abstain _____	Absent _____
Ramon Miguez, PE	Yes_____	No _____	Abstain _____	Absent _____
Farida Minner, RN	Yes_____	No _____	Abstain _____	Absent _____
Yasmin Simon	Yes_____	No _____	Abstain _____	Absent _____

Consideration and Appropriate Action Regarding Fiscal 8311-1-04 Investment Policy

Fiscal 8311-1-04 Investment Policy

Requirements regarding this document are found in:

- The Texas Health & Safety Code 281.049

Background:

- Last published 12/19/24 (1-year approval period).

Revisions:

- Add investment management firm Hilltop Securities as a source of education
- Update language surrounding investments in mortgage-backed securities
- Add investor liquidity needs as a reason for the investment manager to sell securities prior to maturity
- Revise some outdated terms
- Remove mortgage pool securities as approved investments

Approvals:

- Joe Mayer, Treasury Director
- Rick Humphrey, CFO
- Board Budget and Finance Committee (scheduled 11/18/25)
- Board of Managers (scheduled 12/17/25)

Investment Policy	8311-1-04	Published: 12/19/24
Fiscal		Page 1 of 16

PURPOSE:

It is the policy of the Dallas County Hospital District (the District), d/b/a Parkland Health, to invest all available hospital operating and bond funds and related reserves in a manner that provides maximum security and the best commensurate yield while meeting the daily cash flow demands of the District and conforming to the legal and administrative guidelines set forth herein. Parkland Community Health Plan, Inc. (PCHP) funds are covered by this Policy, but are managed as separately invested assets.

The purpose of this Investment Policy is to comply with Chapter 2256 of the Texas Government Code (Public Funds Investment Act), which requires each subject entity to adopt a written policy regarding the investment of its funds and funds under its control. The Investment Policy addresses the methods, procedures and practices that must be exercised to ensure effective and judicious fiscal management of the District's funds.

SCOPE:

All Parkland Workforce members.

POLICY:

1. Investment of the funds covered by this Policy shall be governed by the following investment objectives, in order of priority.

   A. Safety: Safety of principal is the primary objective of the Investment Policy. Investment of the District's funds shall be undertaken in a manner that seeks to ensure the preservation of capital for the overall portfolio. To attain this objective, investment in only high-quality securities and diversification are required in order that potential losses on individual securities do not exceed the income generated from the remainder of the portfolio.

   B. Liquidity: The District's investment portfolio shall remain sufficiently liquid to enable the District to meet all operating requirements that might be reasonably anticipated while also seeking maximum yield.

C. Yield: The District's investment portfolio shall be designed with the objective of attaining the best yield, throughout budgetary and economic cycles, commensurate with the District's investment risk constraints and the cash flow characteristics of the portfolio.

2. Investment Officers

A. The District's Board of Managers shall designate by resolution all officers and employees responsible for, and authorized to, manage and invest funds controlled by the District (Investment Officers). The Investment Officers shall be the individuals primarily responsible for investment activity under this Policy. The authority to manage the District's funds is effective until rescinded by the Board of Managers or until termination of the person's employment from the District. A minimum of two Investment Officers shall approve purchases of investment instruments.

~~B.~~ Investment Officers acting in accordance with this policy and all other applicable laws, are relieved of personal responsibility and liability in the management of the investment portfolio, provided that~~:~~

~~C.~~B. ~~T~~ the Investment Officer acts in accordance with the standard of prudence described below~~:~~:

1) The Investment Officer does not act in violation of the ethics and conflict of interest standards contained in this policy;

2) The Investment Officer does not act with reckless disregard, fraud, or intentional misconduct; and

3) Deviations from expectations are reported in a timely fashion to the Board of Managers and appropriate action is taken to control adverse developments.

4) The Board of Managers, at its discretion, may designate an SEC-registered Investment ~~Management~~ Advisor ~~F~~irm ~~as an Investment Officer~~ in order to manage all, or a portion of, the District's invested funds in accordance with this Policy.

3. Investment Training

A. Investment Officers are required to attend at least one training session, provided by an independent source, within twelve months of assuming investment-related duties under this Policy. Such training must include education in investment controls, security risks, strategy risks, market risks, diversification, and compliance with the Public Funds Investment Act. After the initial training session, each Investment Officer is required to receive not less than ten hours of related instruction at least once during a two-year period beginning with the first day of the fiscal year and consists of the next two fiscal years after this date. Current approved training providers are:

1) Government Treasurers' Organization of Texas (GTOT).

2) Government Finance Officer's Assoc. of Texas (GFOAT).

3) Center for Public Management, Univ. of North Texas (UNT).

4) Texas Municipal League (TML).

5) Virtual Learning Concepts (web-based).

6) TexPool Academy Online.

7) Texas State University (web-based).

8) Hilltop Securities, Inc.

~~7)~~9) North Central Texas Council of Governments (NCTCOG)

B. Additional training providers may be approved by the Board of Managers and included in the Investment Policy at the next review.

4. Prudence

A. The standard of prudence to be applied by Investment Officers shall be the "prudent investor" rule. This rule states that "Investments shall be made with judgment and care, under circumstances then prevailing, which persons of prudence, discretion and intelligence exercise in the management of their own affairs, not for speculation, but for investment, considering the probable safety of their capital as well as the probable income to be derived".

B. In determining whether an Investment Officer has exercised prudence with respect to an investment decision, the determination shall be made taking into

consideration the investment of all funds over which the official had responsibility rather than consideration as to the prudence of a single investment.

5. Ethics and Conflicts of Interest

   A. Investment Officers involved in the investment process are to refrain from personal business activity that could conflict with proper execution of the investment process, or which could impair their ability to make impartial investment decisions.

   B. Investment Officers must file a disclosure statement with the Texas Ethics Commission and the District's Board of Managers if:

      1) The Investment Officer has a personal business relationship with a business organization offering to engage in an investment transaction with the District; or

      2) The Investment Officer is related within the second degree by affinity or consanguinity (Immediate Family Member), as determined under Chapter 573 of the Texas Government Code (see attachment), to an individual seeking to transact investment business with the District.

   C. An Investment Officer has a personal business relationship with a business organization if:

      1) The Investment Officer or, their Immediate Family Member, owns 5 percent or more of the voting stock or shares of the business organization or owns $5,000 or more of the fair market value of the business organization;

      2) Funds received by the Investment Officer or their Immediate Family Member, from the business organization exceed 5 percent of his/her gross income for the previous year;

      3) The Investment Officer, or their Immediate Family Member is, or has been within the last year, an employee, director or officer of the business organization; or

      4) The Investment Officer or their Immediate Family Member has acquired from the business organization, during the previous year, investments with a book value of $2,500 or more for his/her personal account.

6. Authorized Investments

A. District funds governed by this Policy may be invested in the instruments described below, all of which are authorized by the Public Funds Investment Act. Investment of District funds in any instrument or security not authorized for investment under the Public Funds Investment Act is prohibited.

B. An investment that requires a minimum rating under this section does not qualify as an authorized investment during the period the investment does not have the minimum rating. The District (and Investment Officer) shall take all prudent measures consistent with this Policy to liquidate an investment that does not have the minimum rating.

C. Authorized:

1) Obligations, including letters of credit, of the United States of its agencies and instrumentalities.

2) Direct obligations of the State of Texas or its agencies and instrumentalities.

3) Other obligations, the principal and interest of which are unconditionally guaranteed or insured by or backed by the full faith and credit of the State of Texas or the United States or their respective agencies or instrumentalities.

4) Obligations of states, agencies, counties, cities, and other political subdivisions of any state having been rated as to investment quality by a nationally recognized investment rating firm and having received a rating of not less than A or its equivalent.

5) Fully collateralized Certificates of Deposit issued by state or national banks domiciled in this state that are:

a) guaranteed or insured by the Federal Deposit Insurance Corporation (FDIC), or its successor; or

b) secured by authorized investments described in 1 – 4 above (which are intended to include all direct federal agency or instrumentality issued mortgage-backed securities) that have a market value of not less than 102% of the principal amount, plus accrued interest, of the certificates, or

in any other manner and amount provided by law for deposits of public entities.

6) Fully collateralized repurchase agreements, provided the District has on file a signed Master Repurchase Agreement which details eligible collateral, collateralization ratios, standards for collateral custody and control, collateral valuation, and conditions for agreement termination and also provided that the repurchase agreement:

   a) has a defined termination date;

   b) is secured by obligations of the United States or its agencies and instrumentalities that have a market value of not less than the principal amount, plus accrued interest, of the repurchase agreement;

   c) requires the securities being purchased by the District to be assigned to the District, held in the District's name, and deposited at the time of the investment is made with the District's custodian or a third-party selected and approved by the District; and

   d) is placed through a primary government securities dealer, as defined by the Federal Reserve, or a financial institution doing business in this state.

7) Domestic commercial paper with a stated maturity of 270 days or less which is rated not less than A-1, P-1, or an equivalent rating by two nationally recognized rating agencies.

8) No-load money market mutual funds that are registered with and regulated by the Securities and Exchange Commission that:

   a) have a dollar-weighted average stated maturity of ~~90~~ 60 days or fewer;

   b) seek to maintain a stable net asset value of $1 per share; and

   c) have provided the District with a prospectus and other information required by the Securities Exchange Act of 1934 or the Investment Company Act of 1940.

   d) maintain a minimum rating of AAAm or equivalent by at least one nationally recognized rating agency.

9) The Public Funds Investment Act restricts investment in any one mutual fund in an amount that exceeds 10 percent of the total assets of the mutual fund.

10) Local Government Investment Pools created under the Interlocal Cooperation Act of Texas and which conform to the requirements set forth in Section 2256.016 of the Public Funds Investment Act that:

a) have a dollar-weighted average stated maturity of ~~90~~ 60 days or fewer;

b) seek to maintain a stable net asset value of $1 per share; and

c) have provided the District with a prospectus and other information as appropriate; and

d) maintain a minimum rating of AAAm or equivalent by at least one nationally recognized rating agency.

~~11) Mortgage pass-through securities directly issued by a Federal Agency or Instrumentality of the United States, including Government National Mortgage Association ("GNMA or Ginnie Mae"), Federal National Mortgage Association ("FNMA or Fannie Mae") or Federal Home Loan Mortgage Corporation ("FHLMC or Freddie Mac"), collectively referred to as "Agency Mortgage Backed Securities" or "Agency MBS." Such eligible Agency MBS securities consist of pools of 15-year and 30-year residential mortgages that are in compliance with criteria established by each of the government sponsored mortgage issuers, including provisions for maximum principal, loan-to-value and borrower credit qualifications. As such, each agency mortgage issuer guarantees the payment of principal and interest to investors in their respective pass-through securities, and the principal due investors is secured by a first lien against the underlying residential properties.~~

D. Not Authorized:

1) Obligations whose payment represents the coupon payments on the outstanding principal balance of the underlying mortgage-backed security collateral and pays no principal.

2) Obligations whose payment represents the principal stream of cash flow from the underlying mortgage-backed security collateral and bears no interest.

3) Collateralized mortgage obligations.

4) Short sales, margin purchases, or leverage in the portfolio.

5) Option or futures contracts, commodities, or direct real estate investments.

6) Corporate bonds, convertible bonds, or equity shares.

7) Obligations of any foreign banks or other entities issued outside of the United States.

7. Investment Selection

A. It is the policy of the District to require competitive bidding for all individual security purchases and sales except for:

1) Transactions with money market mutual funds and local government investment pools (which are deemed to be made at prevailing market rates);

2) Treasury and agency securities purchased at issue through an approved broker/dealer or financial institution; or

3) Investments purchased by an ~~Investment Management Firm~~ Registered Investment Advisor.

B. At least three bids or offers must be solicited and documented for all other transactions involving individual securities. In situations where the exact security being offered is not offered by other broker/dealers, offers on the closest comparable investment may be used to establish a fair market price for the security.

8. Sale of Securities

A. The District ~~may~~ intends to hold securities to maturity. However, securities may be sold with explicit approval of the VP & Controller, Sr. VP-Finance, or the Executive VP & Chief Financial Officer for purposes of liquidity, safety, or yield enhancement. Investments ~~administered~~ managed by a~~n~~ Registered Investment ~~Management Firm~~ Advisor may be ~~actively traded~~ sold before maturity provided the strategy adds value through issue selection, yield curve structure, convexity, and diversification in order to provide safety of principal and lower portfolio risks or if the investor requires liquidity from the portfolio.

9. Diversification and Maximum Maturities

A. The District attempts to match its investments with anticipated cash flow requirements. Unless matched to a specific cash flow, the District will not directly invest in:

1) Individual securities maturing more than ten (10) years from the date of purchase.

2) Individual eligible Agency MBS as defined previously herein that exhibit average life characteristics and price sensitivity that exceeds that of a five (5) year security. While each eligible mortgage pool will specify a stated final maturity equal to the last contractual payment date due on the mortgages in the pool, such mortgage pass-through pools exhibit aggregate monthly cash flows that create predictable price volatility or average life / average maturity characteristics significantly shorter than the stated final maturity of the pool. (Example: a 30-year FNMA 6.00% mortgage pool may have a "stated final maturity" of 2035~~,~~ but exhibit an average maturity of only three and a half (3.5) years). Mortgage pass-through securities otherwise authorized by this section must have average life / price sensitivity characteristics less than five (5) years at the time of purchase.

3) In order to ensure the ability to meet obligations and to minimize potential liquidation losses, the dollar-weighted average maturity (WAM) of the District's pooled portfolio shall not exceed two (2) years. For the PCHP portfolio, the WAM shall not exceed 2 years. The portion of the District's pooled portfolio managed by an Investment ~~Management Firm~~ Advisor shall not have a WAM greater than three (3) years. In addition, the individual investment portfolios of the District and PCHP will each be diversified to limit market and credit risk by observing the following limitations:

Investment Type	Maximum Portfolio Ratio	Maturity Limit	Minimum Rating
U.S. Treasuries	100% Overall	10 years	N/A
U.S. Agencies & Instrumentalities	100% Overall 40% per Issuer	10 years	AA
Municipals	10% Overall 5% per Issuer	5 years	AA
Certificates of Deposit	40% Overall	2 years	N/A
Repurchase Agreements	40% Overall 20% per Issuer	270 days	N/A
Commercial Paper	40% Overall 5% per Issuer	270 days	A1 – P1
Money Market Mutual Funds	100% Overall	N/A	AAAm
Local Government Investment Pools	100% Overall	N/A	AAAm
~~U.S. Agency/ Instrumentality Mortgage Pass-Through Securities~~	~~25% Overall~~	5 years *	~~AAA~~ AA
• ~~Eligible securities must exhibit average life / maturity characteristics less than 5 years at the time of purchase.~~			

10. Authorized Broker Dealers

A. Any broker/dealer wishing to do business with the District must provide the following:

1) most recent audited financial statements;

2) proof of current certification by the Financial Industry Regulatory Authority (FINRA~~; formerly the National Association of Securities Dealers (NASD)~~); or

3) proof of current registration with the Texas State Securities Commission;

4) completed Broker/Dealer Questionnaire;

5) resumes of designated brokers.

B. The Treasury Director reviews all submitted documents, checks backgrounds and references as may be appropriate, and presents findings and recommendations to the Investment Officers.

C. The Investment Officers, after consideration of the broker/dealer's qualifications, may propose acceptance of the application to the Board of Managers.

~~D. Approved broker/dealers are provided with a copy of the District's Investment Policy so that they may read and understand the District's investment parameters. A qualified representative of the approved broker/dealer firm must execute a written instrument acknowledging that the firm has:~~

~~received and reviewed the District's Investment Policy;~~ and

If the District has hired an Investment Advisor, the advisor shall state that it has

implemented reasonable procedures and controls in an effort to preclude investment transactions conducted between the District and the organization that are not authorized by the District's Investment Policy, except to the extent that this authorization is dependent on an analysis of the makeup of the District's entire portfolio or requires an interpretation of subjective investment standards.

~~E.~~D. The list of approved broker/dealers must be reviewed, no less than annually, by the Board of Managers.

11. Delivery vs. Payment

    A. All marketable securities are purchased using the delivery vs. payment method. Payment for securities purchased is made only upon verification that the correct securities were received by the custodian. Payment may be made in a simultaneous transaction but may not be made before delivery of the securities occurs.

12. Safekeeping and Custody:

    A. The District shall contract with a bank or banks for safekeeping of securities either owned by the District as part of its investment portfolio or held as collateral to secure demand or time deposits. Securities owned by the District shall be held in the District's name as evidenced by safekeeping receipts of the institution holding the securities.

    B. Collateral for bank deposits shall be held by a third-party custodian designated by the District and pledged to the District as evidenced by safekeeping receipts of the institution with which the collateral is deposited. Collateral may be held by the depository bank's trust department, a Federal Reserve Bank or branch of a Federal Reserve Bank, a Federal Home Loan Bank, or a third-party bank approved by the District.

13. Collateral

    A. Consistent with the requirements of the Public Funds Collateral Act, the District requires full collateralization of all uninsured collected bank balances plus accrued interest, if any. In order to anticipate market changes and provide a level of security for all funds, the collateralization level will be 102% of market value of principal and accrued interest on deposits, less the amount insured by the FDIC. The Treasury Director is responsible for approving pledges, releases, and substitutions of collateral and for monitoring the market value of the pledged securities to ensure that it is adequate. Eligible collateral shall be limited to Authorized Investments A) – D) of section 6 of this Policy.

14. Strategy

A. For the Parkland and PCHP portfolios, investments are generally "laddered" to mature according to forecasted cash needs and are held to maturity. In addition, the portfolios are conservatively invested according to the following considerations listed in order of importance:

1) Suitability - All investments will be placed in appropriate instruments that are allowed by this Policy and with which the District's Investment Officers are thoroughly familiar.

2) Safety - Investments will be placed in instruments that offer low credit risk and minimal price volatility with the primary objective of preserving invested principal.

3) Liquidity - Securities will be selected to mature according to forecasted cash needs and to provide for contingencies.

4) Marketability - In order to further protect the District's assets from loss in the event that an early liquidation becomes necessary or desirable, a healthy trading market must exist for any securities maturing more than six (6) months from the purchase date.

5) Diversification - The investment portfolios will be diversified among specific issuers and investment types according to this Policy in order to minimize exposure to market and credit risk.

6) Yield - Investments will be selected which maximize return on invested principal subject to the above considerations.

7) Trading – Trading securities with the intent to profit from short-term changes in interest rates and/or security valuations is only permitted by an Investment Management Firm.

15. Portfolio Reporting and Controls

A. Not less than quarterly, the Treasury Director shall prepare a report of investment activity for presentation to the Board of Managers. This report will describe the investment position for the end of the period. The report will detail balances and changes in market and book values as well as fully accrued interest for the reporting period; state the maturity date of each investment held as of the reporting date; and state the compliance of the investment portfolio with this

Investment Policy. Market values will be obtained from a reputable and independent source that is disclosed in the quarterly report. This report will be signed by the Board authorized Investment Officers.

B. In connection with the annual financial audit, a review of management controls on investments and adherence to this Policy will be performed and the results will be reported to the Board of Managers. The annual audit by the District's independent auditors will include a review of the quarterly investment reports, the results of which shall be presented to the Board of Managers.

16. Investment ~~Management Firms~~ Advisors

A. The District may contract with an ~~accredited investment management firm~~ SEC-Registered Investment Advisor for purposes of managing the DCHD and PCHP investment portfolios. The firm must be registered either under the ~~federal~~ Investment Advisors Act of 1940 or with the Texas State Securities Board. The firm is required to review this policy and confirm acceptance of its terms annually. The firm will only be accountable for the DCHD and PCHP assets in the custody accounts under its control. In accordance with the Public Funds Investment Act, the DCHD Board of Managers must approve by resolution the renewal of the investment management firm's contract every two years.

17. Investment Policy Review and Adoption

A. Not less than annually, the Board of Managers shall adopt a written instrument by resolution stating that it has reviewed the Investment Policy and that the written instrument so adopted shall record any changes made to the Policy.

DEFINITIONS:

Workforce member: An Officer, board member, employee, volunteer, member of the medical staff, contractor, vendor, trainee, or other person whose conduct, in the performance of work for Parkland, is under the direct control of Parkland, whether or not he or she is paid by Parkland.

REFERENCES:

N/A

APPENDIX 1

Consanguinity and Affinity Relationship Chart

Officer or Employee					
Consanguinity (Includes individuals related by blood to the Officer or Employee)			Affinity (Includes the Officer's or Employee's Spouse and individuals related to the Spouse)		
First Degree	Second Degree	Third Degree	First Degree	Second Degree	Third Degree
Father or Mother	Grandparents	Great Grandparents	Spouse	Grandparents	Great Grandparents
Son or Daughter (& Spouse)	Grandchildren (& Spouse)	Great Grandchildren (& Spouse)	Father or Mother	Grandchildren	Great Grandchildren
	Uncle or Aunt (& Spouse)	Great Uncle or Aunt (& Spouse)	Son or Daughter	Uncle or Aunt	Great Uncle or Aunt
	First Cousin (& Spouse)	Children of Great Uncle or Aunt (& Spouse)		First Cousin	Children of Great Uncle or Aunt
	Nephew or Niece (& Spouse)	Second Cousin (& Spouse)		Nephew or Niece	Second Cousin
	Brother or Sister (& Spouse)	Children of First Cousin (& Spouse)		Brother or Sister	Children of First Cousin
		Grand Nephew or Niece (& Spouse)			Grand Nephew or Niece

An Officer or Employee is the starting point from which all degrees of relationship are calculated. Under the Degrees of Consanguinity, where Spouse is indicated, the relationship of the spouse is in the same degree as that of the person related by consanguinity, but the spouse is related only by affinity.

Parkland

Investment Policy	8311-1-04	Published: 12/19/24
Fiscal		Page 1 of 15

PURPOSE:

It is the policy of the Dallas County Hospital District (the District), d/b/a Parkland Health, to invest all available hospital operating and bond funds and related reserves in a manner that provides maximum security and the best commensurate yield while meeting the daily cash flow demands of the District and conforming to the legal and administrative guidelines set forth herein. Parkland Community Health Plan, Inc. (PCHP) funds are covered by this Policy, but are managed as separately invested assets.

The purpose of this Investment Policy is to comply with Chapter 2256 of the Texas Government Code (Public Funds Investment Act), which requires each subject entity to adopt a written policy regarding the investment of its funds and funds under its control. The Investment Policy addresses the methods, procedures and practices that must be exercised to ensure effective and judicious fiscal management of the District's funds.

SCOPE:

All Parkland Workforce members.

POLICY:

1. Investment of the funds covered by this Policy shall be governed by the following investment objectives, in order of priority.

   A. Safety: Safety of principal is the primary objective of the Investment Policy. Investment of the District's funds shall be undertaken in a manner that seeks to ensure the preservation of capital for the overall portfolio. To attain this objective, investment in only high-quality securities and diversification are required in order that potential losses on individual securities do not exceed the income generated from the remainder of the portfolio.

   B. Liquidity: The District's investment portfolio shall remain sufficiently liquid to enable the District to meet all operating requirements that might be reasonably anticipated while also seeking maximum yield.

C. Yield: The District's investment portfolio shall be designed with the objective of attaining the best yield, throughout budgetary and economic cycles, commensurate with the District's investment risk constraints and the cash flow characteristics of the portfolio.

2. Investment Officers

A. The District's Board of Managers shall designate by resolution all officers and employees responsible for, and authorized to, manage and invest funds controlled by the District (Investment Officers). The Investment Officers shall be the individuals primarily responsible for investment activity under this Policy. The authority to manage the District's funds is effective until rescinded by the Board of Managers or until termination of the person's employment from the District. A minimum of two Investment Officers shall approve purchases of investment instruments.

B. Investment Officers acting in accordance with this policy and all other applicable laws, are relieved of personal responsibility and liability in the management of the investment portfolio, provided that the Investment Officer acts in accordance with the standard of prudence described below:

1) The Investment Officer does not act in violation of the ethics and conflict of interest standards contained in this policy;

2) The Investment Officer does not act with reckless disregard, fraud, or intentional misconduct; and

3) Deviations from expectations are reported in a timely fashion to the Board of Managers and appropriate action is taken to control adverse developments.

4) The Board of Managers, at its discretion, may designate an SEC-registered Investment Advisor i which meets industry standards in order to manage all, or a portion of, the District's invested funds in accordance with this Policy.

3. Investment Training

A. Investment Officers are required to attend at least one training session, provided by an independent source, within twelve months of assuming investment-related duties under this Policy. Such training must include education in investment controls, security risks, strategy risks, market risks, diversification, and

compliance with the Public Funds Investment Act. After the initial training session, each Investment Officer is required to receive not less than ten hours of related instruction at least once during a two-year period beginning with the first day of the fiscal year and consists of the next two fiscal years after this date. Current approved training providers are:

1) Government Treasurers' Organization of Texas (GTOT).
2) Government Finance Officer's Assoc. of Texas (GFOAT).
3) Center for Public Management, Univ. of North Texas (UNT).
4) Texas Municipal League (TML).
5) Virtual Learning Concepts (web-based).
6) TexPool Academy Online.
7) Texas State University (web-based).
8) Hilltop Securities, Inc.
9) North Central Texas Council of Governments (NCTCOG)

B. Additional training providers may be approved by the Board of Managers and included in the Investment Policy at the next review.

4. Prudence

A. The standard of prudence to be applied by Investment Officers shall be the "prudent investor" rule. This rule states that "Investments shall be made with judgment and care, under circumstances then prevailing, which persons of prudence, discretion and intelligence exercise in the management of their own affairs, not for speculation, but for investment, considering the probable safety of their capital as well as the probable income to be derived".

B. In determining whether an Investment Officer has exercised prudence with respect to an investment decision, the determination shall be made taking into consideration the investment of all funds over which the official had responsibility rather than consideration as to the prudence of a single investment.

5. Ethics and Conflicts of Interest

A. Investment Officers involved in the investment process are to refrain from personal business activity that could conflict with proper execution of the investment process, or which could impair their ability to make impartial investment decisions.

B. Investment Officers must file a disclosure statement with the Texas Ethics Commission and the District's Board of Managers if:

1) The Investment Officer has a personal business relationship with a business organization offering to engage in an investment transaction with the District; or

2) The Investment Officer is related within the second degree by affinity or consanguinity (Immediate Family Member), as determined under Chapter 573 of the Texas Government Code (see attachment), to an individual seeking to transact investment business with the District.

C. An Investment Officer has a personal business relationship with a business organization if:

1) The Investment Officer or, their Immediate Family Member, owns 5 percent or more of the voting stock or shares of the business organization or owns $5,000 or more of the fair market value of the business organization;

2) Funds received by the Investment Officer or their Immediate Family Member, from the business organization exceed 5 percent of his/her gross income for the previous year;

3) The Investment Officer, or their Immediate Family Member is, or has been within the last year, an employee, director or officer of the business organization; or

4) The Investment Officer or their Immediate Family Member has acquired from the business organization, during the previous year, investments with a book value of $2,500 or more for his/her personal account.

6. Authorized Investments

A. District funds governed by this Policy may be invested in the instruments described below, all of which are authorized by the Public Funds Investment Act.

Investment of District funds in any instrument or security not authorized for investment under the Public Funds Investment Act is prohibited.

B. An investment that requires a minimum rating under this section does not qualify as an authorized investment during the period the investment does not have the minimum rating. The District (and Investment Officer) shall take all prudent measures consistent with this Policy to liquidate an investment that does not have the minimum rating.

C. Authorized:

1) Obligations, including letters of credit, of the United States of its agencies and instrumentalities.

2) Direct obligations of the State of Texas or its agencies and instrumentalities.

3) Other obligations, the principal and interest of which are unconditionally guaranteed or insured by or backed by the full faith and credit of the State of Texas or the United States or their respective agencies or instrumentalities.

4) Obligations of states, agencies, counties, cities, and other political subdivisions of any state having been rated as to investment quality by a nationally recognized investment rating firm and having received a rating of not less than A or its equivalent.

5) Fully collateralized Certificates of Deposit issued by state or national banks domiciled in this state that are:

a) guaranteed or insured by the Federal Deposit Insurance Corporation (FDIC), or its successor; or

b) secured by authorized investments described in 1 – 4 above (which are intended to include all direct federal agency or instrumentality issued mortgage-backed securities) that have a market value of not less than 102% of the principal amount, plus accrued interest, of the certificates, or in any other manner and amount provided by law for deposits of public entities.

6) Fully collateralized repurchase agreements, provided the District has on file a signed Master Repurchase Agreement which details eligible collateral,

collateralization ratios, standards for collateral custody and control, collateral valuation, and conditions for agreement termination and also provided that the repurchase agreement:

a) has a defined termination date;

b) is secured by obligations of the United States or its agencies and instrumentalities that have a market value of not less than the principal amount, plus accrued interest, of the repurchase agreement;

c) requires the securities being purchased by the District to be assigned to the District, held in the District's name, and deposited at the time of the investment is made with the District's custodian or a third-party selected and approved by the District; and

d) is placed through a primary government securities dealer, as defined by the Federal Reserve, or a financial institution doing business in this state.

7) Domestic commercial paper with a stated maturity of 270 days or less which is rated not less than A-1, P-1, or an equivalent rating by two nationally recognized rating agencies.

8) No-load money market mutual funds that are registered with and regulated by the Securities and Exchange Commission that:

a) have a dollar-weighted average stated maturity of 60 days or fewer;

b) seek to maintain a stable net asset value of $1 per share; and

c) have provided the District with a prospectus and other information required by the Securities Exchange Act of 1934 or the Investment Company Act of 1940.

d) maintain a minimum rating of AAAm or equivalent by at least one nationally recognized rating agency.

9) The Public Funds Investment Act restricts investment in any one mutual fund in an amount that exceeds 10 percent of the total assets of the mutual fund.

10) Local Government Investment Pools created under the Interlocal Cooperation Act of Texas and which conform to the requirements set forth in Section 2256.016 of the Public Funds Investment Act that:

a) have a dollar-weighted average stated maturity of 60 days or fewer;

b) seek to maintain a stable net asset value of $1 per share; and

c) have provided the District with a prospectus and other information as appropriate; and

d) maintain a minimum rating of AAAm or equivalent by at least one nationally recognized rating agency.

D. Not Authorized:

1) Obligations whose payment represents the coupon payments on the outstanding principal balance of the underlying mortgage-backed security collateral and pays no principal.

2) Obligations whose payment represents the principal stream of cash flow from the underlying mortgage-backed security collateral and bears no interest.

3) Collateralized mortgage obligations.

4) Short sales, margin purchases, or leverage in the portfolio.

5) Option or futures contracts, commodities, or direct real estate investments.

6) Corporate bonds, convertible bonds, or equity shares.

7) Obligations of any foreign banks or other entities issued outside of the United States.

7. Investment Selection

A. It is the policy of the District to require competitive bidding for all individual security purchases and sales except for:

1) Transactions with money market mutual funds and local government investment pools (which are deemed to be made at prevailing market rates);

2) Treasury and agency securities purchased at issue through an approved broker/dealer or financial institution; or

3) Investments purchased by an Registered Investment Advisor.

B. At least three bids or offers must be solicited and documented for all other transactions involving individual securities. In situations where the exact security being offered is not offered by other broker/dealers, offers on the closest comparable investment may be used to establish a fair market price for the security.

8. Sale of Securities

A. The District intends to hold securities to maturity. However, securities may be sold with explicit approval of the VP & Controller, Sr. VP-Finance, or the Executive VP & Chief Financial Officer for purposes of liquidity, safety, or yield enhancement. Investments managed by a Registered Investment Advisor may be sold before maturity provided the strategy adds value through issue selection, yield curve structure, convexity, and diversification in order to provide safety of principal and lower portfolio risks or if the investor requires liquidity from the portfolio.

9. Diversification and Maximum Maturities

A. The District attempts to match its investments with anticipated cash flow requirements. Unless matched to a specific cash flow, the District will not directly invest in:

1) Individual securities maturing more than ten (10) years from the date of purchase.

2) Individual eligible Agency MBS as defined previously herein that exhibit average life characteristics and price sensitivity that exceeds that of a five (5) year security. While each eligible mortgage pool will specify a stated final maturity equal to the last contractual payment date due on the mortgages in the pool, such mortgage pass-through pools exhibit aggregate monthly cash flows that create predictable price volatility or average life / average maturity characteristics significantly shorter than the stated final maturity of the pool. (Example: a 30-year FNMA 6.00% mortgage pool may have a "stated final maturity" of 2035but exhibit an average maturity of only three and a half (3.5)

years). Mortgage pass-through securities otherwise authorized by this section must have average life / price sensitivity characteristics less than five (5) years at the time of purchase.

3) In order to ensure the ability to meet obligations and to minimize potential liquidation losses, the dollar-weighted average maturity (WAM) of the District's pooled portfolio shall not exceed two (2) years. For the PCHP portfolio, the WAM shall not exceed 2 years. The portion of the District's pooled portfolio managed by an Investment Advisor shall not have a WAM greater than three (3) years. In addition, the individual investment portfolios of the District and PCHP will each be diversified to limit market and credit risk by observing the following limitations:

Parkland

Investment Type	Maximum Portfolio Ratio	Maturity Limit	Minimum Rating
U.S. Treasuries	100% Overall	10 years	N/A
U.S. Agencies & Instrumentalities	100% Overall 40% per Issuer	10 years	AA
Municipals	10% Overall 5% per Issuer	5 years	AA
Certificates of Deposit	40% Overall	2 years	N/A
Repurchase Agreements	40% Overall 20% per Issuer	270 days	N/A
Commercial Paper	40% Overall 5% per Issuer	270 days	A1 – P1
Money Market Mutual Funds	100% Overall	N/A	AAAm
Local Government Investment Pools	100% Overall	N/A	AAAm
		5 years *	AA
•			

10. Authorized Broker Dealers

A. Any broker/dealer wishing to do business with the District must provide the following:

1) most recent audited financial statements;

2) proof of current certification by the Financial Industry Regulatory Authority (FINRA)); or

3) proof of current registration with the Texas State Securities Commission;

4) completed Broker/Dealer Questionnaire;

5) resumes of designated brokers.

B. The Treasury Director reviews all submitted documents, checks backgrounds and references as may be appropriate, and presents findings and recommendations to the Investment Officers.

C. The Investment Officers, after consideration of the broker/dealer's qualifications, may propose acceptance of the application to the Board of Managers.

If the District has hired an Investment Advisor, the advisor shall state that it has implemented reasonable procedures and controls in an effort to preclude investment transactions conducted between the District and the organization that are not authorized by the District's Investment Policy, except to the extent that this authorization is dependent on an analysis of the makeup of the District's entire portfolio or requires an interpretation of subjective investment standards.

D. The list of approved broker/dealers must be reviewed, no less than annually, by the Board of Managers.

11. Delivery vs. Payment

A. All marketable securities are purchased using the delivery vs. payment method. Payment for securities purchased is made only upon verification that the correct securities were received by the custodian. Payment may be made in a simultaneous transaction but may not be made before delivery of the securities occurs.

12. Safekeeping and Custody:

    A. The District shall contract with a bank or banks for safekeeping of securities either owned by the District as part of its investment portfolio or held as collateral to secure demand or time deposits. Securities owned by the District shall be held in the District's name as evidenced by safekeeping receipts of the institution holding the securities.

    B. Collateral for bank deposits shall be held by a third-party custodian designated by the District and pledged to the District as evidenced by safekeeping receipts of the institution with which the collateral is deposited. Collateral may be held by the depository bank's trust department, a Federal Reserve Bank or branch of a Federal Reserve Bank, a Federal Home Loan Bank, or a third-party bank approved by the District.

13. Collateral

    A. Consistent with the requirements of the Public Funds Collateral Act, the District requires full collateralization of all uninsured collected bank balances plus accrued interest, if any. In order to anticipate market changes and provide a level of security for all funds, the collateralization level will be 102% of market value of principal and accrued interest on deposits, less the amount insured by the FDIC. The Treasury Director is responsible for approving pledges, releases, and substitutions of collateral and for monitoring the market value of the pledged securities to ensure that it is adequate. Eligible collateral shall be limited to Authorized Investments A) – D) of section 6 of this Policy.

14. Strategy

    A. For the Parkland and PCHP portfolios, investments are generally "laddered" to mature according to forecasted cash needs and are held to maturity. In addition, the portfolios are conservatively invested according to the following considerations listed in order of importance:

        1) Suitability - All investments will be placed in appropriate instruments that are allowed by this Policy and with which the District's Investment Officers are thoroughly familiar.

2) Safety - Investments will be placed in instruments that offer low credit risk and minimal price volatility with the primary objective of preserving invested principal.

3) Liquidity - Securities will be selected to mature according to forecasted cash needs and to provide for contingencies.

4) Marketability - In order to further protect the District's assets from loss in the event that an early liquidation becomes necessary or desirable, a healthy trading market must exist for any securities maturing more than six (6) months from the purchase date.

5) Diversification - The investment portfolios will be diversified among specific issuers and investment types according to this Policy in order to minimize exposure to market and credit risk.

6) Yield - Investments will be selected which maximize return on invested principal subject to the above considerations.

7) Trading – Trading securities with the intent to profit from short-term changes in interest rates and/or security valuations is only permitted by an Investment Management Firm.

15. Portfolio Reporting and Controls

A. Not less than quarterly, the Treasury Director shall prepare a report of investment activity for presentation to the Board of Managers. This report will describe the investment position for the end of the period. The report will detail balances and changes in market and book values as well as fully accrued interest for the reporting period; state the maturity date of each investment held as of the reporting date; and state the compliance of the investment portfolio with this Investment Policy. Market values will be obtained from a reputable and independent source that is disclosed in the quarterly report. This report will be signed by the Board authorized Investment Officers.

B. In connection with the annual financial audit, a review of management controls on investments and adherence to this Policy will be performed and the results will be reported to the Board of Managers. The annual audit by the District's independent auditors will include a review of the quarterly investment reports, the results of which shall be presented to the Board of Managers.

16. Investment Advisors

A. The District may contract with an SEC-Registered Investment Advisor for purposes of managing the DCHD and PCHP investment portfolios. The firm must be registered either under the Investment Advisors Act of 1940 or with the Texas State Securities Board. The firm is required to review this policy and confirm acceptance of its terms annually. The firm will only be accountable for the DCHD and PCHP assets in the custody accounts under its control. In accordance with the Public Funds Investment Act, the DCHD Board of Managers must approve by resolution the renewal of the investment management firm's contract every two years.

17. Investment Policy Review and Adoption

A. Not less than annually, the Board of Managers shall adopt a written instrument by resolution stating that it has reviewed the Investment Policy and that the written instrument so adopted shall record any changes made to the Policy.

DEFINITIONS:

Workforce member: An Officer, board member, employee, volunteer, member of the medical staff, contractor, vendor, trainee, or other person whose conduct, in the performance of work for Parkland, is under the direct control of Parkland, whether or not he or she is paid by Parkland.

REFERENCES:

N/A

APPENDIX 1

Consanguinity and Affinity Relationship Chart

Officer or Employee					
Consanguinity (Includes individuals related by blood to the Officer or Employee)			Affinity (Includes the Officer's or Employee's Spouse and individuals related to the Spouse)		
First Degree	Second Degree	Third Degree	First Degree	Second Degree	Third Degree
Father or Mother	Grandparents	Great Grandparents	Spouse	Grandparents	Great Grandparents
Son or Daughter (& Spouse)	Grandchildren (& Spouse)	Great Grandchildren (& Spouse)	Father or Mother	Grandchildren	Great Grandchildren
	Uncle or Aunt (& Spouse)	Great Uncle or Aunt (& Spouse)	Son or Daughter	Uncle or Aunt	Great Uncle or Aunt
	First Cousin (& Spouse)	Children of Great Uncle or Aunt (& Spouse)		First Cousin	Children of Great Uncle or Aunt
	Nephew or Niece (& Spouse)	Second Cousin (& Spouse)		Nephew or Niece	Second Cousin
	Brother or Sister (& Spouse)	Children of First Cousin (& Spouse)		Brother or Sister	Children of First Cousin
		Grand Nephew or Niece (& Spouse)			Grand Nephew or Niece

An Officer or Employee is the starting point from which all degrees of relationship are calculated. Under the Degrees of Consanguinity, where Spouse is indicated, the relationship of the spouse is in the same degree as that of the person related by consanguinity, but the spouse is related only by affinity.

Consideration and Appropriate Action Regarding Authorizing Officer for the 340B Program

PARKLAND HEALTH
BOARD OF MANAGERS

RESOLUTION NO. _____

RESOLUTION

Be it resolved, the Dallas County Hospital District Board of Managers by a vote of ____ Yes and ___ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS the Dallas County Hospital District is a political subdivision of the State of Texas and does business as Parkland Health ("Parkland"); and

WHEREAS Parkland previously adopted the Purchasing Practices and Procedures Manual ("Manual"), and

WHEREAS Parts 2-201 and 2-203 of the Manual confer authority of the Chief Executive Officer to appoint Contracting Officers with signature authority with approval of the Parkland Board of Managers; and

THEREFORE, **BE IT RESOLVED,** that the Parkland Board of Managers approves the following Contracting Officer appointment subject to the limitations and restrictions set forth below:

> **Carrie Berge** – Effective December ___, 2025, Frederick P. Cerise, M.D., President and Chief Executive Officer of Dallas County Hospital District d/b/a Parkland Health, hereby grants authority to Carrie Berge, Vice President, Pharmacy Services, to perform all Authorizing Official ("AO") activities required under the 340B Drug Pricing Program as defined by the U.S. Department of Health & Human Services, Health Resources and Services Administration ("HRSA"). This delegation of authority shall include the authority to legally bind Parkland into agreements with the Federal government for the purposes of certifying/recertifying and effectuating Parkland's eligibility and participation in the 340B Drug Purchasing Program and to complete the required attestations on behalf of Parkland regarding Parkland's compliance with the 340B Drug Pricing Program requirements. This authority is specifically limited to AO functions necessary to effectuate the 340B program and does not include the authority to make purchases on behalf of Parkland.

Dated this _____ day of _____, 2025.

Marjorie Petty, JD Chair	Todd Furniss, JD Secretary

Marjorie Petty, JD	Yes _____	No _____	Abstain _____	Absent _____
Eric G. Bing, MD, PhD	Yes _____	No _____	Abstain _____	Absent _____
Byron Cryer, MD	Yes _____	No _____	Abstain _____	Absent _____
Todd Furniss, JD	Yes _____	No _____	Abstain _____	Absent _____
Reina Gonzalez, JD	Yes _____	No _____	Abstain _____	Absent _____
Vincent Hall	Yes _____	No _____	Abstain _____	Absent _____
Ramon Miguez, PE	Yes _____	No _____	Abstain _____	Absent _____
Farida Minner, RN	Yes _____	No _____	Abstain _____	Absent _____
Elizabeth Palacios, MD	Yes _____	No _____	Abstain _____	Absent _____
Yasmin Simon, JD	Yes _____	No _____	Abstain _____	Absent _____
Lisa Sutter	Yes _____	No _____	Abstain _____	Absent _____

Consideration and Appropriate Action Regarding - Investment Committee Report and Recommendation – Private Markets Investment Manager

Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH

RESOLUTION NO. _____

RESOLUTION

Be it resolved, the Dallas County Hospital District Board of Managers by a vote of _____YES and ____ NAY, does by this resolution (adopt/reject) _____the following:

WHEREAS, the Medical Executive Committee recommends approval of the Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers as presented.

THEREFORE BE IT RESOLVED that the Board of Managers approves the recommended Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers.

Dated this 17th of December 2025

_____ _____

Marjorie D. Petty, JD
Chair

Steve Roth, JD, MPH
Assistant Secretary

Marjorie D. Petty, JD	Yes_____ No_____ Abstain _____Absent_____
Elizabeth Palacios, MD	Yes_____ No_____ Abstain _____Absent_____
Todd Furniss, JD	Yes_____ No_____ Abstain _____Absent_____
Eric G. Bing, MD, PhD	Yes_____ No_____ Abstain _____Absent_____
Byron Cryer, MD	Yes_____ No_____ Abstain _____Absent_____
Reina Gonzalez, JD	Yes_____ No_____ Abstain _____Absent_____
Vincent Hall	Yes_____ No_____ Abstain _____Absent_____
Ramon Miguez, PE	Yes_____ No_____ Abstain _____Absent_____
Farida Minner, RN	Yes_____ No_____ Abstain _____Absent_____
Lisa Sutter	Yes_____ No_____ Abstain _____Absent_____
Yasmin Simon, JD	Yes_____ No_____ Abstain _____Absent_____

Governance Update and Discussion Regarding Key Upcoming Dates and the Board Self-Assessment

CEO Update on System Operations

Parkland Pension Plan Funding Status

Parkland Debt Capacity and Alternatives

Break

Discussion Regarding Potential New Service Lines and Property Acquisition

Executive Session Documents

Possible Deliberation Regarding Medical Executive Committee Credentialing Report

Possible Deliberation Regarding Medical Executive Committee Delineation of Privileges Oral and Maxillofacial Surgery (OMFS)

Possible Deliberation Regarding Medical Executive Committee Delineation of Privileges Internal Medicine

Possible Deliberation Regarding Medical Executive Committee Delineation of Privileges Endocrinology

Possible Deliberation Regarding Medical Executive Committee Delineation of Privileges Gastroenterology

Possible Deliberation Regarding Medical Executive Committee Delineation of Privileges Infectious Disease

Information Only

Possible Deliberation Regarding Q3 Sole Source Report

Fiscal Year 2025
Third Quarter
Sole Source Report

Per Parkland Purchasing Practices and Procedures Manual Section 3.205.04 and Dallas County Code 78-66(8), Parkland Management will inform the Board of Managers of the sole source record. Per the Dallas County Code the report will be made at the next regular meeting so the reporting data is presented quarterly.

Parkland

Spend Analysis, FY 2025, 3rd Quarter



Spend Type	Number of Requisitions	Requisition Amount	% of Total Spend
Approved Emergency	3	$110,845	0.08%
Approved Sole Source	199	$51,446,775	38.01%
Other PO Spend	41688	$83,600,583	61.77%

Information Only

Possible Deliberation Regarding Q4 Sole Source Report

Fiscal Year 2025
Fourth Quarter
Sole Source Report

Per Parkland Purchasing Practices and Procedures Manual Section 3.205.04 and Dallas County Code 78-66(8), Parkland Management will inform the Board of Managers of the sole source record. Per the Dallas County Code the report will be made at the next regular meeting so the reporting data is presented quarterly.

Spend Analysis. FY 2025, 4th Quarter



Spend Type	Number of Requisitions	Requisition Amount	% of Total Spend
Approved Emergency	3	$1,301,553	1.23%
Approved Sole Source	156	$34,991,713	33.19%
Other PO Spend	42977	$68,197,486	64.68%

Information Only

Possible Deliberation Regarding Board of Managers Attendance Report

Information Only

Possible Deliberation Regarding Board of Managers Meeting Evaluation Report